阅读说明：本技术 抗感染杂环化合物及其用途 (Anti-infective heterocyclic compounds and uses thereof ) 是由 莱夫·基尔塞布姆 拉姆·尚卡尔·乌帕德哈雅雅 拉加瓦·雷迪·凯斯里 安德斯·弗塔嫩 于 2018-11-05 设计创作，主要内容包括：本发明涉及可用作抗感染剂的具有式F-I的杂环化合物。本发明进一步涉及通过施用此类化合物治疗感染的方法,以及包含此类化合物的药物组合物。<Image he="344" wi="540" file="DDA0002497911810000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(The present invention relates to heterocyclic compounds having the formula F-I useful as anti-infective agents. The invention further relates to methods of treating infections by administering such compounds, and pharmaceutical compositions comprising such compounds.)

1. A compound having the formula F-I:

or a pharmaceutically acceptable salt thereof

Wherein

X⁵Selected from CH, CMe, C ═ O, and N;

in when X⁵Is CH, CMe or N represents a double bond, and when X is⁵Represents a single bond when C ═ O;

R¹selected from the group consisting of:

-R²、-(CH₂)_m-R²、-C(O)-R²and-CHMe-R²；

R²Selected from the group consisting of:

optionally substituted by one or more groups selected from-halogen and-C_1-3A-phenyl group substituted with a group of alkyl groups,

-C_3-10cycloalkyl, wherein the cycloalkyl group is monocyclic, bicyclic or polycyclic and is optionally substituted by one or more groups selected from-F and-Me,

-C_1-10an alkyl group, wherein the alkyl group is linear or branched,

-C_2-10alkenyl, wherein the alkeneThe radical being straight-chain or branched, and

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic heterocycle;

R³selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-(CH₂)_n-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶；

R⁴selected from the group consisting of:

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C_3-6a cycloalkyl group,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-phenyl substituted with a group of-hydroxy,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-benzyl substituted with a hydroxy group,

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more groups selected from-benzyl, -halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-hydroxy;

R⁵selected from the group consisting of:

-H、

optionally substituted by one or more groups selected from-halogen and-C_1-3-benzyl substituted by alkyl groups,

-C_1-6Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂；

or

R⁴And R⁵Together with the atom to which they are bonded form a heteroaliphatic ring;

R⁶selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A 3-6 membered monocyclic cycloalkyl substituted by a group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷A 3-6 membered monocyclic cycloalkyl substituted by a group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷The substitution of the group(s),

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Substituted by groups;

or

R⁵And R⁶Together with the atom to which they are bonded form an optionally substituted R⁷A group-substituted heteroaliphatic ring;

R⁷selected from the group consisting of: -halogen, -C_1-3Alkyl, aryl, heteroaryl, and heteroaryl,-C_1-3Alkoxy, phenyl, hydroxy, -CH₂OH, -oxo, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph, mono-or di-C_1-3Alkylamine, -C (O) -NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)-NH-R⁸And-phenoxy optionally substituted with-Cl;

R⁸selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl;

R⁹and R¹⁰Each independently selected from the group consisting of: -H, -halogen, -C_1-3Alkyl radical, -C_1-3Perfluoroalkyl radical, -C_2-3Alkoxy radical, -C_1-3Perfluoroalkoxy, -NO₂，-OH，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-halogen, -C_1-3Alkyl, -C_1-3Perfluoroalkyl, -C_1-3Alkoxy, -C_1-3Perfluoroalkoxy substituted-phenyl; and is

Wherein m, n, p, r, s and t are each independently selected from 0, 1 and 2.

2. The compound of claim 1 having F-II:

or a pharmaceutically acceptable salt thereof

Wherein

R²Selected from the group consisting of:

-phenyl optionally substituted with one or more groups selected from-F and-Me,

-C_3-10cycloalkyl, wherein the cycloalkaneThe radical is cyclopropyl, cycloheptyl, bicycloheptyl or adamantyl, optionally substituted with one or more groups selected from-F and-Me,

-C_1-10an alkyl group, wherein the alkyl group is ethyl, isopropyl or octyl,

-C_2-10alkenyl, wherein the alkenyl group is linear or branched, and

-heterocyclyl, wherein the heterocyclyl group is piperidinyl or hexahydropyranyl;

R³selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH₂-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶；

R⁴selected from the group consisting of:

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C selected from the group consisting of cyclopropyl, cyclopentyl and cyclohexyl_3-6A cycloalkyl group,

optionally substituted by one or more groups selected from-F, -Cl, -Me, -iPr, -CF₃、-OMe、OCF₃A-phenyl group substituted with the group of (a),

-benzyl optionally substituted with one or more methyl groups,

-heterocyclyl, wherein the heterocyclyl group is imidazolyl, thiazolyl, pyridyl, piperidinyl, tetrahydropyranyl, quinolinyl or isoquinolinyl, and is optionally substituted with one or more groups selected from-benzyl, and-hydroxy;

R⁵selected from the group consisting of:

-H、

-benzyl, -benzyl optionally substituted by one or more groups selected from-F and-Me,

-C_1-2Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂；

or

R⁴And R⁵Together with the atom to which they are bonded form a 6 membered heteroaliphatic ring;

R⁶selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is pyrrolidinyl, pyridinyl, imidazolyl, thiazolyl, piperidinyl, furanyl, benzodioxolyl, oxazolyl, morpholinyl, or tetrahydropyranyl, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷The substitution of the group(s),

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Substituted by groups;

or

R⁵And R⁶Together with the atom to which they are bonded form a 6 membered heteroaliphatic ring optionally substituted with one or more R⁷Substituted by groups;

R⁷selected from the group consisting of: methyl, fluoro, bromo, phenyl, hydroxy, -CH₂OH, -oxo, methoxy, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph、-NH₂、-NHMe、-NMe₂、-C(O)-NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)NH-R⁸And phenoxy optionally substituted with-Cl;

R⁸selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl;

R⁹selected from the group consisting of: -H, -F, -Br, -NO₂，-OH，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-Cl, -Me, -CF₃-OMe or

-OCF₃Substituted-phenyl;

R¹⁰is-H or-Br; and is

X⁵、R¹M, n, p, r, s and t are as defined in claim 1.

3. The compound of any one of claims 1 or 2 having formula F-III:

or a pharmaceutically acceptable salt thereof

Wherein R is¹¹is-H, -Me or-oxo;

at when R is¹¹Represents a double bond when it is-H or-Me, and when R is¹¹Is oxo representsA single bond.

4. The compound of any one of the preceding claims having F-IV:

or a pharmaceutically acceptable salt thereof.

5. The compound of any one of claims 1-3 having formula F-V:

or a pharmaceutically acceptable salt thereof.

6. The compound of any one of claims 1-3 having formula VI:

or a pharmaceutically acceptable salt thereof,

wherein v is a number of 0 or 1,

z is selected from the group consisting of CH or N,

and wherein

Whenever Z is CH, R¹²is-NR⁵R⁶And is and

whenever Z is N, R¹²Selected from R containing at least one N atom⁷A group.

7. The compound of any one of claims 1-5, wherein

R¹Is cyclohexyl or n-octyl;

n is 2;

R⁴selected from the group consisting of: -Cy, -PhOCF₃And pentane-3-yl;

R⁵is H;

R⁶is- (CH)₂)₃-NH₂or-Cy-NH₂；

R⁹is-H or-CN; and is

R¹⁰Is H.

8. The compound of claim 6, wherein

R¹Is cyclohexyl or n-octyl;

R⁹is-H or-CN; and is

R¹⁰Is H.

9. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.

10. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use according to claim 9, wherein the therapy is the treatment or prevention of an infection.

11. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein the infection is a bacterial, fungal or parasitic infection.

12. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein the infection is a bacterial infection caused by or concurrent with a bacterium of a genus selected from: staphylococcus, enterococcus, Streptococcus, Pseudomonas, Legionella, Klebsiella, Haemophilus, Neisseria, Listeria, Escherichia, helicobacter, and Mycobacterium.

13. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, for use according to claim 12, wherein the bacterial infection is caused by or concurrent with a bacterial species selected from the group consisting of: staphylococcus aureus, enterococcus faecalis, enterococcus faecium, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Acinetobacter baumannii, Pseudomonas aeruginosa, Neisseria gonorrhoeae, helicobacter pylori, Neisseria meningitidis, Listeria monocytogenes, Legionella pneumophila, Mycobacterium bovis, and Mycobacterium tuberculosis.

14. A method of treating an infection, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 8.

15. The method of claim 14, wherein the infection is a bacterial, fungal, or parasitic infection.

16. The method of claim 15, wherein the infection is a bacterial infection caused by or concurrent with a bacterium of a genus selected from the group consisting of: staphylococcus, enterococcus, Streptococcus, Pseudomonas, Legionella, Klebsiella, Haemophilus, Neisseria, Listeria, Escherichia, helicobacter, and Mycobacterium.

17. The method of claim 16, wherein the bacterial infection is caused by or is concurrent with a bacterial species selected from the group consisting of: staphylococcus aureus, enterococcus faecalis, enterococcus faecium, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Acinetobacter baumannii, Pseudomonas aeruginosa, Neisseria gonorrhoeae, helicobacter pylori, Neisseria meningitidis, Listeria monocytogenes, Legionella pneumophila, Mycobacterium bovis, and Mycobacterium tuberculosis.

18. Use of a compound according to any one of claims 1 to 8, or a salt thereof, for inhibiting bacterial rnase P activity.

19. Use of a compound according to any one of claims 1 to 8, or a salt thereof, as a bactericide.

20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, adjuvant, diluent and/or carrier.

Technical Field

The present invention relates to heterocyclic compounds useful as anti-infective agents. The invention further relates to methods of inhibiting infection by administering such compounds. The invention further relates to pharmaceutical compositions comprising such compounds.

Background

Antimicrobial resistance poses an increasing threat to global public health. New resistance mechanisms emerge and spread worldwide, threatening the effective prevention and treatment of a range of infections caused by bacteria, parasites and fungi.

Many examples may be provided to illustrate the threat posed. In 2013, there were approximately 50 million new multidrug resistant cases of tuberculosis. Resistance to artemisinin-based combination therapies, the best available method for malaria of Plasmodium falciparum (plsimdium falciparum), has been detected in the mei-mex region. Higher drug resistant bacteria (e.g., MRSA) can cause a number of hospital acquired infections and also begin to spread throughout the community. Patients with such resistant infections have poorer clinical outcomes and increased risk of death compared to patients infected with non-resistant bacteria. 10 countries have reported cases of non-treatable gonorrhea due to resistance to treatment with the last resort antibiotic (cephalosporin generation 3). Thus, gonorrhea may quickly become untreatable.

This underscores the increased and urgent need for new anti-infective agents for use in therapy.

Disclosure of Invention

It is therefore an object of the present invention to provide compounds useful in the treatment or prevention of infections. It is another object to provide a method of treating infections, such as bacterial, fungal or parasitic infections.

These objects are achieved by compounds as disclosed by the appended claims.

These compounds have the formula F-I:

or a pharmaceutically acceptable salt thereof

Wherein

X⁵Selected from CH, CMe, C ═ O, and N;

in when X⁵Is CH, CMe or N represents a double bond, and when X is⁵Represents a single bond when C ═ O;

R¹selected from the group consisting of:

-R²、-(CH₂)_m-R²、-C(O)-R²and-CHMe-R²；

R²Selected from the group consisting of:

optionally substituted by one or more groups selected from-halogen and-C_1-3A-phenyl group substituted with a group of alkyl groups,

-C_3-10cycloalkyl, wherein the cycloalkyl group is monocyclic, bicyclic or polycyclic and is optionally substituted by one or more groups selected from-F and-Me,

-C_1-10an alkyl group, wherein the alkyl group is linear or branched,

-C_2-10alkenyl, wherein the alkenyl group is linear or branched, and

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic heterocycle;

R³selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-(CH₂)_n-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶；

R⁴selected from the group consisting of:

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C_3-6a cycloalkyl group,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-phenyl substituted with a group of-hydroxy,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-benzyl substituted with a hydroxy group,

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more groups selected from-benzyl, -halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy radicalradical-C_1-3Perhaloalkoxy, and-hydroxy;

R⁵selected from the group consisting of:

-H、

optionally substituted by one or more groups selected from-halogen and-C_1-3-benzyl substituted by alkyl groups,

-C_1-6Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂；

or

R⁴And R⁵Together with the atom to which they are bonded form a heteroaliphatic ring;

R⁶selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A 3-6 membered monocyclic cycloalkyl substituted by a group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷A 3-6 membered monocyclic cycloalkyl substituted by a group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷The substitution of the group(s),

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Substituted by groups;

or

R⁵And R⁶Together with the atom to which they are bonded form an optionally substituted R⁷A group-substituted heteroaliphatic ring;

R⁷selected from the group consisting of: -halogen, -C_1-3Alkyl, -C_1-3Alkoxy, phenyl, hydroxy, -CH₂OH, -oxo, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph, mono-or di-C_1-3Alkylamine, -C (O) -NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)-NH-R⁸And-phenoxy optionally substituted with-Cl;

R⁸selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl;

R⁹and R¹⁰Each independently selected from the group consisting of: -H, -halogen, -C_1-3Alkyl radical, -C_1-3Perfluoroalkyl radical, C_2-3Alkoxy radical, -C_1-3Perfluoroalkoxy, -NO₂，-OH，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-halogen, -C_1-3Alkyl, -C_1-3Perfluoroalkyl, -C_1-3Alkoxy, -C_1-3Perfluoroalkoxy substituted-phenyl; and is

Wherein m, n, p, r, s and t are each independently selected from 0, 1 and 2.

Also disclosed herein are compounds having the formula (I):

or a pharmaceutically acceptable salt thereof

Wherein

X¹、X²、X³And X⁴Each independently selected from C and N;

X⁵selected from CH, CMe, C ═ O, and N;

R¹selected from the group consisting of:

-H、-R²、-(CH₂)_m-R²、-C(O)-R²and-CHMe-R²；

R²Selected from the group consisting of:

optionally substituted by one or more groups selected from-halogen and-C_1-3A-phenyl group substituted with a group of alkyl groups,

-C_3-10cycloalkyl, wherein the cycloalkyl group is monocyclic, bicyclic or polycyclic and is optionally substituted by one or more groups selected from-F and-Me,

-C_1-10an alkyl group, wherein the alkyl group is linear or branched,

-C_2-10alkenyl, wherein the alkenyl group is linear or branched, and

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic heterocycle;

R³selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-(CH₂)_n-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶；

R⁴selected from the group consisting of:

-H，

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C_3-6a cycloalkyl group,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-phenyl substituted with a group of-hydroxy,

optionally substituted by one or more groups selected from-halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-benzyl substituted with a hydroxy group,

-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more groups selected from-benzyl, -halogen, -C_1-3Alkyl, -C_1-3Perhaloalkyl, -C_1-3Alkoxy, -C_1-3Perhaloalkoxy, and-hydroxy;

R⁵selected from the group consisting of:

-H、

optionally substituted by one or more groups selected from-halogen and-C_1-3-benzyl substituted by alkyl groups,

-C_1-6Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂；

or

Wherein R is⁴And R⁵Together with the atom to which they are bonded form a heteroaliphatic ring;

R⁶selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A 3-6 membered monocyclic cycloalkyl substituted by a group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷Substituted by radicalsA 3-6 membered monocyclic cycloalkyl group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is a 5-or 6-membered aliphatic or aromatic, optionally benzo-fused heterocycle, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷The substitution of the group(s),

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Substituted by groups;

or

Wherein R is⁵And R⁶Together with the atom to which they are bonded form an optionally substituted R⁷A group-substituted heteroaliphatic ring;

R⁷selected from the group consisting of: -halogen, -C_1-3Alkyl, -C_1-3Alkoxy, phenyl, hydroxy, -CH₂OH, -oxo, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph, mono-or di-C_1-3Alkylamine, -C (O) -NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)-NH-R⁸And-phenoxy optionally substituted with-Cl;

R⁸selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl;

R⁹and R¹⁰Each independently selected from the group consisting of: -H, -halogen, -C_1-3Alkyl radical, -C_1-3Perfluoroalkyl radical, -C_1-3Alkoxy radical, -C_1-3Perfluoroalkoxy, -NO₂，-OH，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-Me-halogen, -C_1-3Alkyl, -C_1-3Perfluoroalkyl, -C_1-3Alkoxy, -C_1-3Perfluoroalkoxy substituted-phenyl; and is

Wherein m, n, p, r, s and t are each independently selected from 0, 1 or 2.

The compounds or salts as defined by formula I and F-I may therefore be used for the treatment or prevention of infections, especially bacterial infections.

Without wishing to be bound by theory, it is believed that the compounds disclosed above achieve their antibacterial effect at least in part by inhibiting rnase P. Rnase P is a ribonucleoprotein complex present in all living cells and bacteria and is involved in the processing of RNA transcripts, e.g. the removal of the 5' leader sequence from tRNA precursors. In bacteria, rnase P consists of one RNA subunit and a small basic protein, and has been shown to have catalytic activity associated with its RNA subunit. Rnase P is potentially a good drug target because rnase P is essential for bacterial viability and the structure of rnase P differs from bacteria to eukaryotes. For example, the important P-15 loop in bacteria is a good target for antibacterial drug design because it is not present in the human (eukaryotic) RNase P RNA.

These compounds having the formula F-I may belong to a subset of compounds having the formula F-II:

or a pharmaceutically acceptable salt thereof

Wherein

X⁵Selected from CH, CMe, C ═ O, and N;

in when X⁵Is CH, CMe or N represents a double bond, and when X is⁵Represents a single bond when C ═ O;

R¹selected from the group consisting of:

-R²、-(CH₂)_m-R²、-C(O)-R²and-CHMe-R²；

R²Selected from the group consisting of:

-phenyl optionally substituted with one or more groups selected from-F and-Me,

-C_3-10cycloalkyl, wherein the cycloalkyl group is cyclopropyl, cycloheptyl, bicycloheptyl or adamantyl, optionally substituted with one or more groups selected from-F and-Me,

-C_1-10an alkyl group, wherein the alkyl group is ethyl, isopropyl or octyl,

-C_2-10alkenyl, wherein the alkenyl group is linear or branched, and

-heterocyclyl, wherein the heterocyclyl group is piperidinyl or hexahydropyranyl;

R³selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH₂-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶；

R⁴selected from the group consisting of:

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C selected from the group consisting of cyclopropyl, cyclopentyl and cyclohexyl_3-6A cycloalkyl group,

optionally substituted by one or more groups selected from-F, -Cl, -Me, -iPr, -CF₃、-OMe、OCF₃A-phenyl group substituted with the group of (a),

-benzyl optionally substituted with one or more methyl groups,

-heterocyclyl, wherein the heterocyclyl group is imidazolyl, thiazolyl, pyridyl, piperidinyl, tetrahydropyranyl, quinolinyl or isoquinolinyl, and is optionally substituted with one or more groups selected from-benzyl, and-hydroxy;

R⁵selected from the group consisting of:

-H、

-benzyl, -benzyl optionally substituted by one or more groups selected from-F and-Me,

-C_1-2Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂；

or

R⁴And R⁵Together with the atom to which they are bonded form a 6 membered heteroaliphatic ring;

R⁶selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is pyrrolidinyl, pyridinyl, imidazolyl, thiazolyl, piperidinyl, furanyl, benzodioxolyl (benzodioxolyl), oxazolyl, morpholinyl, or tetrahydropyranyl, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷The substitution of the group(s),

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Substituted by groups;

or

R⁵And R⁶Together with the atom to which they are bonded form a 6 membered heteroaliphatic ring optionally substituted with one or more R⁷Substituted by groups;

R⁷selected from the group consisting of: methyl, fluoro, bromo, phenyl, hydroxy, -CH₂OH, -oxo, methoxy, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph、-NH₂、-NHMe、-NMe₂、-C(O)-NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)NH-R⁸And phenoxy optionally substituted with-Cl;

R⁸selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl;

R⁹selected from the group consisting of: -H, -F, -Br, -NO₂，-OH，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-Cl, -Me, -CF₃-OMe or-OCF₃Substituted-phenyl;

R¹⁰is-H or-Br; and is

m, n, p, r, s and t are each independently selected from 0, 1 and 2.

These compounds having the formulas F-I and F-II may belong to a subset of compounds having the formulas F-III:

or a pharmaceutically acceptable salt thereof

Wherein R is¹¹is-H-Me or-oxo;

at when R is¹¹Represents a double bond when it is-H or-Me, and when R is¹¹And represents a single bond when it is oxo.

These compounds having the formulas F-I, F-II and F-III may belong to a subset of compounds having the formula F-IV:

or a pharmaceutically acceptable salt thereof.

These compounds having the formulas F-I, F-II and F-III may belong to a subset of compounds having the formulas F-V:

or a pharmaceutically acceptable salt thereof.

These compounds having the formulas F-I, F-II and F-III may belong to a subset of compounds having the formula VI:

or a pharmaceutically acceptable salt thereof,

wherein v is a number of 0 or 1,

z is selected from the group consisting of CH or N,

and wherein

Whenever Z is CH, R¹²is-NR⁵R⁶And is and

whenever Z is N, R¹²Selected from R containing at least one N atom⁷A group.

These compounds having any of the formulas F-I, F-II, F-IlI, F-IV, and F-V can belong to a subset of the following compounds, wherein:

R¹is cyclohexyl or n-octyl;

n is 2;

R⁴selected from the group consisting of: -Cy, -PhOCF₃And pentane-3-yl;

R⁵is H;

R⁶is- (CH)₂)₃-NH₂or-Cy-NH₂；

R⁹is-H or-CN; and is

R¹⁰Is H.

The compound having formula VI may belong to a subset of compounds wherein:

R¹is cyclohexyl or n-octyl;

R⁹is-H or-CN; and is

R¹⁰Is H.

These compounds having formula I may belong to a subset of compounds having formula II:

or a pharmaceutically acceptable salt thereof.

X¹、X²、X³And X⁴May each independently be selected from C and N, with the proviso that when X is³Is N then X¹Is also N.

X⁵May be selected from CH, CMe, C ═ O, and N.

R¹May be selected from the group consisting of:

-H、-R²、-(CH₂)_m-R²、-C(O)-R²and-CHMe-R²。

R²May be selected from the group consisting of:

-phenyl optionally substituted with one or more groups selected from-F and-Me,

-C_3-10cycloalkyl, wherein the cycloalkyl group is cyclopropyl, cycloheptyl, bicycloheptyl or adamantyl, optionally substituted with one or more groups selected from-F and-Me,

-C_1-10an alkyl group, a carboxyl group,wherein the alkyl group is ethyl, isopropyl or octyl,

-C_2-10alkenyl, wherein the alkenyl group is linear or branched, and

-heterocyclyl, wherein the heterocyclyl group is piperidinyl or hexahydropyranyl.

R³May be selected from the group consisting of:

-CH(R⁴)-(CH₂)_n-C(O)NR⁵R⁶、

-CH(R⁴)-(CH₂)_n-NHR⁵、

-CH(R⁴)-(CH₂)_n-NR⁵R⁶、

-CH₂-CH(NH₂)-C(O)NR⁵R⁶、

-C(O)-NR⁵R⁶、

-Cy-NR⁵R⁶and, and

-CH(R⁴)-(CH₂)_n-OR⁶。

R⁴may be selected from the group consisting of:

-H，

-C_1-6an alkyl group, wherein the alkyl group is linear or branched,

-C selected from the group consisting of cyclopropyl, cyclopentyl and cyclohexyl_3-6A cycloalkyl group,

optionally substituted by one or more groups selected from-F, -Cl, -Me, -iPr, -CF₃、-OMe、OCF₃A-phenyl group substituted with the group of (a),

optionally substituted by one or more methyl groups-C_1-3Alkyl-substituted-benzyl, and

-heterocyclyl, wherein the heterocyclyl group is imidazolyl, thiazolyl, pyridyl, piperidinyl, tetrahydropyranyl, quinolinyl or isoquinolinyl, and is optionally substituted with one or more groups selected from-benzyl, and-hydroxy.

R⁵May be selected from the group consisting of:

-H、

-benzyl, -benzyl optionally substituted by one or more groups selected from-F and-Me,

-C_1-2Alkyl, aryl, heteroaryl, and heteroaryl,

-acetyl group,

-CN, and

-(CH₂)₃-NH₂。

R⁴and R⁵Together with the atoms to which they are bonded may form a 6 membered heteroaliphatic ring.

R⁶May be selected from the group consisting of:

optionally substituted by one or more R⁷radical-substituted-C_1-3An alkyl group, a carboxyl group,

-C_0-3alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by one or more R⁷A group-substituted cyclopropyl, cyclopentyl or cyclohexyl group,

-C_0-3alkyl-heterocyclyl, wherein the heterocyclyl group is pyrrolidinyl, pyridinyl, imidazolyl, thiazolyl, piperidinyl, furanyl, benzodioxolyl (benzodioxolyl), oxazolyl, morpholinyl, or tetrahydropyranyl, and is optionally substituted with one or more R⁷The substitution of the group(s),

-C_1-3alkyl-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷Is substituted by radicals, and

-C(O)-(CH₂)_p-NH-(CH₂)_r-phenyl, wherein the phenyl group is optionally substituted with one or more R⁷And (4) substituting the group.

R⁵And R⁶Together with the atom to which they are bonded may form an optionally substituted R⁷A 6 membered heteroaliphatic ring substituted with a group.

R⁷May be selected from the group consisting of: methyl, fluorine, bromine, phenyl, hydroxyl,-CH₂OH, -oxo, methoxy, -C (O) Me, -SO₂Me, optionally-F-substituted-SO₂Ph、-NH₂、-NHMe、-NMe₂、-C(O)-NH₂、-NH-C(O)-NH₂、-C(＝NH)-NH₂、-NH-C(＝NH)-NH₂、-(CH₂)_s-NH₂Piperidine, piperazine, morpholine, - (CH)₂)_t-NH-P(O)(OEt)₂、-C(O)NH-R⁸And phenoxy optionally substituted with-Cl.

R⁸May be selected from the group consisting of: -OH, - (amino) cyclohexyl, -pyrrolidinylethyl, and-methylpiperazinylethyl.

R⁹May be selected from the group consisting of: -H, -F, -Br, -NO₂，-OH，-OMe，-CN，-CO₂H，-CO₂Me，-CO₂NH₂，-CH₂NH₂-Cy, -pyridinyl, -tetrahydropyridinyl, pyrazinyl optionally substituted with-Me, and optionally substituted with-Cl, -Me, -CF₃-OMe or-OCF₃Substituted-phenyl.

R¹⁰May be-H or-Br.

m, n, p, r, s and t may each independently be selected from 0, 1 or 2.

These compounds having formula I or II may belong to a subset of compounds having formula III:

or a pharmaceutically acceptable salt thereof

Wherein R is¹¹is-H, -Me or-oxo.

These compounds having formulas I-III may belong to a subset of compounds having formula IV:

or a pharmaceutically acceptable salt thereof.

These compounds having any of formulas I-III may belong to a subset of compounds having formula V:

or a pharmaceutically acceptable salt thereof.

These compounds having any of formulas I-III can belong to a subset of compounds having formula VI:

or a pharmaceutically acceptable salt thereof,

wherein v is a number of 0 or 1,

z is selected from the group consisting of CH or N,

and wherein

Whenever Z is CH, R¹²is-NR⁵R⁶And is and

whenever Z is N, R¹²Selected from R containing at least one N atom⁷A group.

These compounds having any one of formulas I-VI may belong to a subset of compounds wherein:

R¹is cyclohexyl or n-octyl;

n is 2;

R⁴selected from the group consisting of: -Cy, -PhOCF₃And pentane-3-yl;

R⁵is H;

R⁶is- (CH)₂)₃-NH₂or-Cy-NH₂；

R⁹is-H or-CN; and is

R¹⁰Is H.

These compounds having any one of formulas I-V may belong to a subset of compounds wherein:

X¹-X⁴are each C, and X⁵Is CH.

According to another aspect of the invention the object of the invention is achieved by a compound according to formula F-I, I or II as disclosed above, or any subset thereof, for use in a method of treatment of the human or animal body by therapy. The therapy may be treatment or prevention of infection. The infection may be a bacterial, fungal or parasitic infection. The infection may be a bacterial infection caused by or concurrent with a bacterium of a genus selected from the group consisting of: staphylococcus, enterococcus, Streptococcus, Pseudomonas, Legionella, Klebsiella, Haemophilus, Neisseria, Listeria, Escherichia, helicobacter, and Mycobacterium. The bacterial infection may be caused by or concurrent with a bacterial species selected from the group consisting of: staphylococcus aureus, enterococcus faecalis, enterococcus faecium, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Acinetobacter baumannii, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Mycobacterium fortuitum, Mycobacterium phlei, and helicobacter pylori. The bacterial infection may be caused by or concurrent with a bacterial species selected from the group consisting of: neisseria meningitidis, Listeria monocytogenes, Legionella pneumophila, Mycobacterium bovis, and Mycobacterium tuberculosis. Bacterial infections may be caused by or concurrent with methicillin-resistant staphylococcus aureus (MRSA).

According to another aspect of the invention, the object of the invention is achieved by a method of treating an infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound as disclosed above. The infection may be a bacterial, fungal or parasitic infection. The infection may be a bacterial infection caused by or concurrent with a bacterium of a genus selected from the group consisting of: staphylococcus, enterococcus, Streptococcus, Pseudomonas, Legionella, Klebsiella, Haemophilus, Neisseria, Listeria, Escherichia, helicobacter, and Mycobacterium. The bacterial infection may be caused by or concurrent with a bacterial species selected from the group consisting of: staphylococcus aureus, enterococcus faecalis, enterococcus faecium, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Acinetobacter baumannii, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Mycobacterium fortuitum, Mycobacterium phlei, and helicobacter pylori. The bacterial infection may be caused by or concurrent with a bacterial species selected from the group consisting of: neisseria meningitidis, Listeria monocytogenes, Legionella pneumophila, Mycobacterium bovis, and Mycobacterium tuberculosis. Bacterial infections may be caused by or concurrent with methicillin-resistant staphylococcus aureus.

According to yet another aspect of the invention, the object of the invention is achieved by the use of a compound or a salt thereof as disclosed above for inhibiting the activity of bacterial rnase P.

According to yet another aspect of the invention, the object of the invention is achieved by the use of a compound as disclosed above or a salt thereof as a fungicide.

According to yet another aspect of the invention, the object of the invention is achieved by a pharmaceutical composition comprising a compound as disclosed above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, adjuvant, diluent and/or carrier.

Other aspects, objects, and advantages are defined in the following detailed description with reference to the accompanying drawings.

Drawings

For an understanding of the present invention, together with other objects and advantages thereof, reference is made to the following detailed description taken in conjunction with the accompanying drawings.

Figure 1 shows scheme 1 for the synthesis of selected compounds according to the invention.

Figure 2 shows scheme 2 for the synthesis of selected compounds according to the invention.

Figure 3 shows scheme 3 for the synthesis of selected compounds according to the invention.

Figure 4 shows general scheme 1 for the synthesis of selected compounds according to the present invention.

Figure 5 shows a synthetic scheme for the synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile dihydrochloride according to the present invention.

Figure 6 shows general scheme 2 for the synthesis of selected compounds according to the present invention.

Figure 7 shows general scheme 3 for the synthesis of selected compounds according to the present invention.

Figure 8 shows general scheme 4 for the synthesis of selected compounds according to the present invention.

Figure 9 shows general scheme 5A for the synthesis of selected compounds according to the present invention.

Figure 10 shows general scheme 5B for the synthesis of selected compounds according to the present invention.

Figure 11 shows general scheme 6 for the synthesis of selected compounds according to the present invention.

FIG. 12 shows a synthetic scheme for the synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -3- (1- (cyclohexylmethyl) -5-phenyl-1H-indol-3-yl) -3- (m-tolyl) propionamide according to the present invention.

Figure 13 shows general scheme 8 for the synthesis of selected compounds according to the present invention.

Figure 14 shows general scheme 9 for the synthesis of selected compounds according to the present invention.

Figure 15 shows general scheme 10 for the synthesis of selected compounds according to the present invention.

Figure 16 shows general scheme 11 for the synthesis of selected compounds according to the present invention.

Detailed Description

General synthetic method

All reactions were carried out under a dry nitrogen and or argon atmosphere unless otherwise indicated. Unless otherwise indicated, all raw starting materials, solvents and reagents were purchased from commercial sources (e.g., AVRA Chemicals (avrachemics), Apollo Scientific Limited, Bepharma Limited (Bepharma Ltd.), conbine (Combi-Blocks Inc.), Sigma Aldrich Chemicals private company, ltra Labs, toronto research Chemicals Inc., Chemical House, RFCL Limited (RFCL Limited), spectrochemical private company, spectral Chemical company, spectral Chem (pvc). Alternatively, the reagents may be synthesized by procedures known in the literature.

The following abbreviations are used and have the specified definitions: MHz is megahertz (frequency), m is multiplet, t is triplet, d is doublet, s is singlet, br is broad, CDCl₃Is deuterated chloroform, calcd is calculated, min is minutes, h is hours, g is grams, mmol is millimolar, mL is milliliters, N is the normality (concentration), M is the molarity (concentration), μ M is micromolar, ee is the enantiomeric excess, de is the diastereomeric excess, DEG C is degrees Celsius, HPLC is high performance liquid chromatography, LC-MS is liquid chromatography-mass spectrometry, NMR is nuclear magnetic resonance, TLC is thin layer chromatography, THF is tetrahydrofuran, MeOH is methanol, DCM is dichloromethane, DEA is diethylamine, DMA is dimethylacetamide, DMF is N, N-dimethylformamide, DMSO is dimethylsulfoxide, EtOH is ethanol, EtOAc is ethyl acetate, RT is room temperature, HCl is hydrogen chloride or hydrochloric acid, TFA is trifluoroacetic acid, EtMgBr is ethylmagnesium bromide, N-BuLi is N-butyllithium, NaHCO is ethyl alcohol, N-dimethylformamide is ethyl acetate, and₃is sodium bicarbonate, Na₂CO₃Is sodium carbonate, Na₂SO₄Is sodium sulfate, DCC is N, N-dicyclohexylcarbodiimide, DIPA is diisopropylamine, LDA is lithium diisopropylamide, HOBt is N-hydroxy-benzotriazole, NCS is N-chlorosuccinimide, and TBAB is tetrabutylammonium bromide.

BiotageOne and(TeledyeneIsco) automatic flash purification System for purification of crude product using the eluent combination mentioned in the corresponding procedure Using silica gel (60-100, 100-200 and 230-400 mesh) from ChemLabs, flash chromatography with nitrogen and/or compressed air, GF 1500. mu.M 20 × cm and GF 2000. mu.M 20 84 cm preliminary etching Using silica gel (Analtech, Inc. Delaware, USA) from Anilel technologies, Delaware, USA)Traceplate) was subjected to preparative thin layer chromatography. Using a pre-coated silica gel sheet (Merck 60F)₂₅₄) Thin layer chromatography was performed. And performing visual detection by using ultraviolet light, p-anisaldehyde coloring agent, ninhydrin coloring agent, dinitrophenylhydrazine coloring agent, potassium permanganate coloring agent or iodine. By using a cold bath (e.g. 0 ℃ H)₂O/ice and-78 ℃ acetone/dry ice) at a lower temperature. Melting points were determined by using a LabIndia MR-VIS visual melting Range apparatus. Using tetramethylsilane as an internal reference, at ambient temperature using a Varian V400 spectrometer, Bruker 400 (unless otherwise noted) was recorded at 400MHz¹H NMR spectrum. Chemical shift values are expressed in parts per million. Use ofUPLC-SQD (Waters) and Agilent 1290 with 6150 SQD machineMass spectra of all intermediates and final compounds were recorded. Using Agilent 1290HPLC spectra were recorded using a Kinetex C18(50mm × 2.1.1 mm × 2.7.7 mic) and/or X-terra MS C18(50mm × 2.1.1 mm × 3.0.0 micron) column using AgilentLCMS/AgilentUHPLC-SQD with Diode Array Detector (DAD) detection LC-MS instruments record LCMS spectra. Using a device with SQDPDA or with 6150 SQD instrumentDAD measures the purity of each final compound.

The compounds according to formula I and II are prepared using conventional organic synthesis methods. Suitable synthetic routes are depicted below in the following general reaction schemes.

One skilled in the art will appreciate that if a substituent described herein is incompatible with the synthetic methods described herein, the substituent may be protected with a suitable protecting group that is stable to the reaction conditions. The protecting group may be removed at a suitable point in the reaction sequence to provide the desired intermediate or target compound. Suitable protecting groups and methods for protecting and deprotecting various substituents using such suitable protecting groups are well known to those skilled in the art; examples of which can be found in t.greene and p.wuts,Protecting Groups in Organic Synthesis[ protecting group in organic Synthesis](4 th edition), John Wiley&Sons [ John Willi international publishing Co., Ltd]New york (2006). In some cases, the substituents may be specifically selected to be reactive under the reaction conditions used. In these cases, the reaction conditions convert the selected substituent to another substituent that can be used as an intermediate compound or as a desired substituent in the target compound.

Scheme 1 (fig. 1) shows a synthetic route to synthesize a compound having general formula (Ia) from compound (Ia) or compound (If). Reductive amination of (Ia) with the appropriate aldehyde or ketone of R1 affords the N-substituted indolenine derivative (Ib) which upon oxidation gives the indole derivative (Ic). The compound having the formula (Id) is prepared by reacting with R₂-CHO and a Mandrolic ester are obtained from the compound of formula (Ic) by condensation reaction, followed by reaction with Cu and ethanol to give the compound of formula (Ie).

On the other hand, the compound having formula (Ie) may be obtained from an indole derivative (If). Compounds (Ig) prepared by reaction with the appropriate R₂CHO and Meldrum's acid from (If) and subsequent decarboxylation and esterification provide the compound having formula (Ih). Alkylation of (Ih) with the appropriate R1X affords the key intermediate (Ie). Reduction of compound (Ie) using procedures known in the literature for the reduction of esters to give compound (Ii) using alkyl or aryl radicalsTreatment with an arylsulfonyl chloride or halogenating agent provides a compound having formula (Ij). Finally, by reacting the compound Ij with the appropriate amine (R)₃R₄NH) to obtain a compound having formula IA. A compound having the formula Ic wherein R₅、R₆In the case of halogen, it can be converted to R by CuCN using a cyanation reaction known in the literature₅、R₆Is CN. On the other hand, under the suzuki coupling known in the literature, the halogen is converted into an aryl, alkyl group. R containing N/O protecting group₁To R₆Deprotection is usually performed when further steps are required or to obtain the final compound.

Scheme 2 (fig. 2) shows a synthetic route to synthesize a compound having formula (IB) from compound 2 a. Hydrolysis of the ester of 2a under basic conditions known in the literature affords compound 2 b. Compounds having formula 2b are as defined above with the corresponding amines NHR₃R₄Reacted to obtain (IB). The reaction can be carried out using conditions commonly used for the synthesis of amides from acids, under suitable coupling agents or by treatment with halogenating or dehydrating reagents.

Scheme 3 (fig. 3) shows a method of preparing a compound having formula (IC). Compound 3a can be prepared by reacting 3a with an unsaturated ketone in the presence of a lewis acid under michael reaction conditions. NHR with the corresponding amine under reductive amination conditions known in the literature₃R₄Compound 3b was treated to give a compound of formula (IC).

General scheme 1 (fig. 4) describes the synthesis of compounds having formulas F-I and I. Reductive amination of indoline derivative I-a with a ketone affords I-b which, under oxidation, yields the N-substituted indole compound I-c via DDQ. When using the corresponding aldehyde R₂-CHO and Meldrum's acid treatment, 3-substituted indole derivatives I-d were obtained from Ic, followed by decarboxylation under Cu-EtOH to give esters I-e. Saponification of I-e by LiOH followed by coupling with the appropriate NHR3R4 gave compound I-g. The amine derivative I-h is given under reduction of I-g amide, which is isolated as a non-polar Boc derivative by treatment with Boc anhydride. Finally, compound I is isolated as the hydrochloride salt by deprotecting I-h under acidic conditions. On the other hand, the ester compound I-e is addedReduction to the alcohol under a protogen (like LiAlH4) to give the corresponding alcohol I-j, treatment of I-j with methanesulfonyl chloride to give the methanesulfonyl derivative I-k, followed by reaction with the appropriate amine NHR³R⁴The metathesis reaction was carried out to give the compound having the formula I-g. If R is₃And R⁴Containing N and O protecting groups, which can be deprotected under various conditions reported in the literature to obtain the final compounds of formulae F-I and I listed in Table 1.

Example I: synthesis of N1- (3- (1- (piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine

Synthesis of 4- (indolin-1-yl) piperidine-1-carboxylic acid tert-butyl ester:

to a stirred solution of indoline (1g, 8.403mmol) in DCM (25mL) was added tert-butyl 4-oxopiperidine-1-carboxylate (4.18g, 21.008mmol) and the reaction mixture was stirred at room temperature for 1h, after which NaBH (OAC) was added at 0 deg.C₃(2.67g, 12.60mmol) the reaction mixture was then stirred at room temperature for 24 h. The progress of the reaction was monitored by TLC. The reaction mixture was washed with NaHCO₃Aqueous solution (30mL) was diluted and compound was extracted with DCM (3 × 50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was used in the next step without further purification (crude wt1.8g).

LC-MS m/z (M): calculating a value 302; found (M + H): 303

Synthesis of tert-butyl 4- (1H-indol-1-yl) piperidine-1-carboxylate:

to a stirred solution of tert-butyl 4- (indolin-1-yl) piperidine-1-carboxylate (2g, 6.622mmol) in THF (20mL) at 0 deg.C was added DDQ (2.2g, 9.933mmol) and the reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (50mL) and extracted with ethyl acetate (3 × 60 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography using 4% EtOAc in petroleum ether as eluent to afford the desired product as a viscous mass (yield: 250mg, 25%).

¹H NMR(400MHz，CDCl₃)7.65(d，J＝4.9Hz，1H)，7.39(d，J＝9.49Hz，2H)，7.23-7.15(m，2H)，7.10(t，J＝7.14Hz，1H)，6.54(d，J＝10.7Hz，1H)，4.40-4.28(m，2H)，2.92(t，J＝12.08Hz，2H)，2.12-2.05(m，2H)，1.94-1.85(m，2H)，1.5(s，10H)

Synthesis of tert-butyl 4- (3- ((2, 2-dimethyl-4, 6-dioxo-1, 3-dioxan-5-yl) (m-tolyl) methyl) -1H-indol-1-yl) piperidine-1-carboxylate:

to a stirred solution of tert-butyl 4- (1H-indol-1-yl) piperidine-1-carboxylate (520mg, 1.73mmol) in dry acetonitrile (6mL) was added Meldrum's acid (499mg, 3.46mmol), m-tolualdehyde (270mg, 2.25mmol) and L-proline (20mg, 0.173mmol) and the reaction mixture was stirred at room temperature for 16H. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated in vacuo and the crude product was used in the next step without purification (crude wt: 1.3 g).

LC-MS m/z (M): calculated value 546.6

Synthesis of ethyl 3- (1- (piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propionate:

to a solution of tert-butyl 4- (3- ((2, 2-dimethyl-4, 6-di-oxo-1, 3-dioxan-5-yl) (m-tolyl) methyl) -1H-indol-1-yl) piperidine-1-carboxylate (1.3g, 2.380mmol) in pyridine and ethanol at a molar ratio of 1: 1 to a stirred solution in mixture (20mL) was added Cu powder (15mg, 0.238mmol) and the reaction mixture was stirred at 90 ℃ for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 60-120 mesh, eluting with 10% EtOAc in petroleum ether) to afford the desired product as a yellow liquid (yield: 600mg, 54%).

Synthesis of 3- (1- (1- (tert-butoxycarbonyl) piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid:

to 3- (1- (1- (tert-butoxycarbonyl) piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid (530mg, 1.08mmol) in THF/MeOH/H at 0 deg.C₂To a stirred solution in O (1: 1) (15mL) was added LiOH (454mg, 10.8mmol) and the reaction mixture was stirred at room temperature for 6 h. The progress of the reaction was monitored by TLC. The reaction mixture was acidified to pH 6 with citric acid. The off-white solid was discarded during acidification, filtered and air dried (yield: 358mg, 71%).

¹H NMR(400MHz，DMSO-d6)7.44(d，J＝7.8Hz，1H)，7.31(d，J＝8.38Hz，1H)，7.20-7.08(m，4H)，7.09-6.98(m，3H)，4.74(t，J＝7.87Hz，1H)，4.38-4.25(m，3H)，3.20-3.12(m，1H)，3.09-3.02(m，1H)，2.90-2.87(m，2H)，2.29(s，3H)，2.10-2.0(m，2H)，1.92-1.84(m，2H)，1.49(s，9H)

LC-MS m/z (M): calculated value 462.59; found (M-H): 461.2

Synthesis of tert-butyl 4- (3- (3- ((4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -3-oxo-1- (m-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate:

to 3- (1- (1- (tert-butoxycarbonyl) piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid (350mg, 0.756mmol) at 0 deg.CTo a stirred solution in DMF (2mL) was added DIPEA (0.270mL, 1.512mmol), HATU (430mg, 1.134mmol) followed by tert-butyl (4-aminocyclohexyl) carbamate (210mg, 0.983mmol) and the reaction mixture stirred at room temperature for 5 h. The progress of the reaction was monitored by TLC. Ice-cold water was added to the reaction mixture at 0 ℃ and extracted with EtOAc. The combined organic layers were passed over Na₂SO₄Dried and concentrated under reduced pressure. The crude compound was purified by column chromatography eluting with 20% EtOAc in petroleum ether to afford the desired product as an off-white solid (yield: 400mg, 80%).

¹H NMR(400MHz，DMSO-d6)7.58(d，J＝7.92Hz，1H)，7.36(d，J＝8.22Hz，1H)，7.26-7.20(m，1H)，7.18-7.08(m，5H)，7.0(d，J＝6.54Hz，1H)，5.28-5.25(m，1H)，4.63(t，J＝7.53Hz，1H)，4.39-4.31(m，3H)，3.85-3.62(m，3H)，3.35-3.2(m，1H)，3.19-3.0(m，8H)，2.30(s，3H)，2.11-2.0(m，2H)，1.91-1.83(m，2H)，1.75-1.70(m，2H)，1.57-1.51(m，20H)，1.40-1.20(m，5H)

LC-MS m/z (M): calculated value 658.87; found (M + H): 659.4

Synthesis of tert-butyl 4- (3- (3- ((4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -1- (m-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate:

to a stirred solution of tert-butyl 4- (3- (3- ((4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -1- (M-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate (200mg, 0.303mmol) in dry THF (8mL) at 0 deg.C was added BH in THF (1M, 4.5mL, 4.553mmol)₃And the reaction mixture was refluxed for 8 h. The progress of the reaction was monitored by TLC. After 8h of reflux, 5mL MeOH were added, followed by 5h of reflux. The solvent was removed from the reaction mixture under reduced pressure and the crude compound was used in the next step without further purification (crude yield 220 mg).

Synthesis of tert-butyl 4- (3- (3- ((tert-butoxycarbonyl) (4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -1- (m-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate:

to a stirred solution of tert-butyl 4- (3- (3- ((4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -1- (m-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate (220mg, 0.34mmol) in DCM (5mL) was added TEA (0.25mL, 1.7mmol), followed by Boc anhydride (0.37mL, 1.7mmol) and the reaction mixture stirred at room temperature for 12H. The progress of the reaction was monitored by TLC. The excess solvent was removed from the reaction mixture and the crude compound was purified by column chromatography using 25% EtOAc in hexanes as eluent to afford the desired compound as a colorless liquid (yield: 65mg, 25%).

Synthesis of N1- (3- (1- (piperidin-4-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine trihydrochloride:

to a stirred solution of tert-butyl 4- (3- (3- ((tert-butoxycarbonyl) (4- ((tert-butoxycarbonyl) amino) cyclohexyl) amino) -1- (M-tolyl) propyl) -1H-indol-1-yl) piperidine-1-carboxylate (65mg, 0.087) in DCM (2mL) at 0 ℃ was added HCl in dioxane (4M, 1.2mL) and the reaction mixture was stirred at room temperature for 2H. The progress of the reaction was monitored by TLC. The excess solvent was removed under reduced pressure and washed with diethyl ether to give an off-white solid (yield: 10mg, 26%).

¹H NMR(400MHz，DMSO-d6)8.90-8.85(m，3H)，8.7(brs，1H)，7.96(brs，1H)，7.53(d，J＝8.1Hz，1H)，7.45(d，J＝8.04Hz，1H)，7.33(s，1H)，7.10-7.19(m，4H)，6.99-6.94(m，2H)，4.70-4.65(m，1H)，4.28-4.25(m，1H)，3.43(d，J＝11Hz，2H)，3.30-3.12(m，5H)，2.95-2.90(m，1H)，2.80-2.72(m，1H)，2.40-2.35(m，1H)，2.25-2.18(m，5H)，2.17-2.12(m，2H)，1.95-1.90(m，1H)，1.80-1.62(m，8H)，

LC-MS m/z (M): calculated value 445.6; found (M + H): 446.4

Synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile dihydrochloride

See fig. 5.

Synthesis of 1-cyclohexyl-1H-indole-5-carbonitrile:

to a stirred solution of 5-bromo-1-cyclohexyl-1H-indole (3g, 11.07mmol) in DMF was added CuCN (2.95g, 33.21mmol) and the reaction mixture was stirred at 140 ℃ for 20H. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ice-cold water (50mL) and extracted with ethyl acetate (3 × 50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography using 5% EtOAc in petroleum ether as eluent to afford the desired product as a colorless viscous liquid (yield: 850mg, 35%).

¹H NMR(400MHz，CDCl₃)7.9(s，1H)，7.41(s，2H)，7.34(d，J＝3.29Hz，1H)，6.58(d，J＝3.25Hz，1H)，4.28-4.19(m，1H)，2.12(d，J＝11.58Hz，2H)，1.96(d，J＝13.47Hz，2H)，1.80-1.85(m，1H)，1.78-1.62(m，2H)，1.53-1.48(m，2H)，1.45-1.23(m，1H)

LC-MS m/z (M): calculated 224.3; found (M + H): 225.2

Synthesis of 1-cyclohexyl-3- ((2, 2-dimethyl-4, 6-dioxo-1, 3-dioxan-5-yl) (3- (trifluoromethoxy) phenyl) methyl) -1H-indole-5-carbonitrile:

to a stirred solution of 1-cyclohexyl-1H-indole-5-carbonitrile (830mg, 3.700mmol) in dry acetonitrile was added Meldrum's acid (959mg, 6.66mmol), 3- (trifluoromethoxy) benzaldehyde (0.68mL, 4.81mmol) and DL-proline (43mg, 0.37mmol) and the reaction mixture was stirred at room temperature for 16H. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated in vacuo and the crude product was used in the next step without purification (crude wt 3.26 g).

LC-MS m/z (M): calculated value 540.5; found (M + H): 541.18

Synthesis of ethyl 3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propionate:

to a stirred solution of 1-cyclohexyl-3- ((2, 2-dimethyl-4, 6-dioxo-1, 3-dioxan-5-yl) (3- (trifluoromethoxy) phenyl) methyl) -1H-indole-5-carbonitrile (3.26g, 6.03mmol) in a 1: 1 mixture of pyridine and ethanol (40mL) was added Cu powder (77mg, 1.206mmol) and the reaction mixture was stirred at 90 ℃ for 16H. The progress of the reaction was monitored by TLC. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 60-120 mesh, eluting with 10% EtOAc in petroleum ether) to afford the desired product as a yellow solid (yield: 1.57g, 87%).

¹H NMR(400MHz，CDCl₃)7.67(s，1H)，7.37(s，2H)，7.36-7.30(m，1H)，7.25-7.20(m，2H)，7.10-7.08(m，2H)，4.78(t，J＝7.91Hz，1H)，4.22-4.16(m，1H)，4.08-4.0(m，2H)，3.12-3.05(m，1H)，3.04-2.95(m，1H)，2.15-2.02(m，3H)，2.0-1.92(m，2H)，1.85-1.79(m，1H)，1.76-1.62(m，2H)，1.52-1.46(m，2H)，1.35-1.24(m，2H)，1.19-1.10(m，3H)

LC-MS m/z (M): calculated value 484.5; found (M + H): 485.2

Synthesis of 1-cyclohexyl-3- (3-hydroxy-1- (3- (trifluoromethoxy) phenyl) propyl) -1H-indole-5-carbonitrile:

to 3- (5-cyano-1-cyclohexyl-1H) at 0 deg.CTo a stirred solution of ethyl (3- (trifluoromethoxy) phenyl) indol-3-yl) -propionate (1.55g, 3.199) in dry THF was added LiBH₄(211mg, 9.597mmol) and the reaction mixture was stirred at 60 ℃ for 10 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice-cold water and extracted with DCM. The combined organic layers were passed over Na₂SO₄Dried and concentrated under reduced pressure. The crude product was used in the next step without purification (crude wt: 1.5 g).

¹H NMR(400MHz，CDCl₃)7.97(s，1H)，7.75(s，1H)，7.67(d，J＝8.65Hz，1H)，7.42-7.38(m，4H)，7.15-7.10(m，1H)，4.50-4.20(m，4H)，3.38-3.36(m，2H)，2.32-2.26(m，1H)，2.20-2.10(m，1H)，1.98-1.88(m，2H)，1.87-1.60(m，6H)，1.58-1.40(m，3H)，1.30-1.20(m，2H)，1.18-1.12(m，1H)

LC-MS m/z (M): calculated 442.4; found (M + H): 443.2

Synthesis of 3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl methanesulfonate:

to 1-cyclohexyl-3- (3-hydroxy-1- (3- (trifluoromethoxy) phenyl) propyl) -1H-indole-5-carbonitrile (520mg, 1.176mmol) in CH at 0 deg.C₂Cl₂To a stirred solution in (6mL) was added TEA (0.33mL, 2.352mmol) followed by dropwise addition of methanesulfonyl chloride (0.11mL, 1.411mmol) and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. Subjecting the reaction mixture to hydrogenation with H₂O (20mL) dilution and addition of the compound with CH₂Cl₂(3X 20mL) and the combined organic layers were extracted with saturated NaHCO₃(20mL) was washed, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude compound was used in the next step without purification (crude wt: 630 g).

LC-MS m/z (M): calculated value 520.5; found (M + H): 521.2

Synthesis of tert-butyl (3- ((3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl) amino) propyl) carbamate:

to a stirred solution of 3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl methanesulfonate (630mg, 1.210mmol) in dry DMF (5mL) was added K2CO₃(500mg, 3.63mmol) and tert-butyl (3-aminopropyl) carbamate (253mg, 1.452mmol) the reaction mixture was then stirred at 80 ℃ for 10 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into ice-cold water (20mL), a solid precipitated, filtered and dissolved in CH₂Cl₂(20mL), concentrated under reduced pressure. Crude compound was passed through preparative TLC (used on CH)₂Cl₂5% Me 0H) to afford the desired product as a light brown liquid (yield: 166mg, 22.9%).

¹H NMR(400MHz，DMSO-d6)7.94(s，1H)，7.75(s，1H)，7.68(d，J＝8.65Hz，1H)，7.42-7.35(m，4H)，7.15-7.10(m，1H)，6.82-6.79(m，1H)，4.42-4.35(m，2H)，4.10-4.05(m，2H)，3.18-3.13(m，5H)，2.96-2.90(m，2H)，2.46-2.40(m，3H)，2.30-2.22(m，1H)，2.20-2.12(m，1H)，1.96-1.88(m，2H)，1.86-1.78(m，4H)，1.76-1.68(m，1H)，1.56-1.48(m，4H)，1.34(s，9H)，1.25-1.20(m，3H)

LC-MS m/z (M): calculated value 598.2; found (M + H): 599.45

Synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile dihydrochloride:

to a stirred solution of tert-butyl (3- ((3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl) amino) propyl) carbamate (160mg, 0.267mmol) in DCM (2mL) at 0 ℃ was added HCl in dioxane (4M, 2mL) and the reaction mixture was stirred at room temperature for 2H. The reaction mixture was concentrated under reduced pressure and the crude compound was washed with diethyl ether to afford the desired compound as an off-white solid (yield: 118mg, 77%), MP: 190-194 deg.C

¹H NMR(400MHz，DMSO-d6)9.38-9.30(m，2H)，8.00-7.70(m，5H)，7.71(d，J＝8.61Hz，1H)，7.44-7.42(m，4H)，7.18(brs，1H)，4.55(t，J＝7.40Hz，1H)，4.42-4.39(m，1H)，3.10-2.77(m，6H)，2.60-2.55(m，1H)，2.43-2.38(m，1H)，1.95-1.93(m，4H)，1.86-1.81(m，4H)，1.77-1.73(m，1H)，1.59-1.42(m，2H)，1.35-1.20(m，2H)

LC-MS m/z (M): calculated value 498.5; found (M + H): 499.3

Synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carboxamide:

to tert-butyl (3- ((3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl) amino) propyl) carbamate (30mg, 0.058mmol) in EtOH: H₂To a stirred solution in O (9: 1) (2mL) was added KOH and the reaction mixture was stirred at 90 ℃ for 50 h. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, acidified with 6N HCl until the pH of the reaction mixture became 1, and the compound was extracted with 10% MeOH in DCM. The organic layer was dried over sodium sulfate and concentrated to provide the desired compound as an off-white solid (yield: 6mg, 25%).

¹H NMR(400MHz，DMSO-d6)8.10(brs，1H)，7.80(brs，1H)，7.68-7.61(m，2H)，7.51(d，J＝8.69Hz，1H)，7.40-7.34(m，3H)，7.13-7.07(m，2H)，4.34(t，J＝11.72Hz，1H)，2.85-2.81(m，2H)，2.74-2.70(m，2H)，2.29-2.25(m，2H)，2.00-1.93(m，2H)，1.89(s，1H)，1.87-1.72(m，7H)，1.54-1.45(m，2H)，1.32-1.22(m，4H)

LC-MS m/z (M): calculated value 516.6; found (M + H): 517.2

The compounds of table 1 were prepared following the procedure described in scheme 1/example a, by using the appropriate starting materials and the appropriate conditions.

TABLE 1

TABLE 1

TABLE 1

TABLE 1

TABLE 1

General scheme 2 (FIG. 6) illustrates the synthetic pathway for compounds F-II and II. Respectively reacting II-a with R₁CH₂X (X ═ leaving group) indole derivative II-b is alkylated, coupled with an aldehyde and a cyclic ester, and subsequently decarboxylated to give ester derivative II-d. Ester hydrolysis II-d followed by coupling with an amine under a coupling reagent provides a compound having formula II or a compound having formula II with a protecting group. Finally, the free base or its salt is given under deprotection according to the reaction conditions. Depending on the maturity of R5, various common functional group transformations were performed. For example, if R₅CN, then BH₃Reduction of II to give II-f, and use of II-f (Boc)₂O treatment to give II-g. Compound XX was obtained by deprotecting the Boc group under acidic conditions. If R3 andR₄containing N and O protecting groups, which can be deprotected under various conditions reported in the literature to obtain the final compounds of formula F-II or II listed in Table 2.

Example II: synthesis of (1S, 4S) -N1- (3- (5- (aminomethyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine

Synthesis of 1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-5-carbonitrile:

to a stirred solution of 1H-indole-5-carbonitrile (1.5g, 10.56mmol) in DMF (8mL) at 0 deg.C was added KI (1.75g, 10.56mmol) followed by addition of NaH (1.26g, 31.68mmol) in portions and the reaction mixture was stirred at the same temperature for 5 min. After 5min, 4- (bromomethyl) tetrahydro-2H-pyran (2.1mL, 15.84mmol) was added to the reaction mixture at 0 ℃ and then stirred at room temperature for 4H. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with crushed ice, stirred for 15min, and the solid obtained in the reaction mixture was filtered off and dried under vacuum to give a light cream solid (yield: 2.25g, 88.9%).

¹H NMR(400MHz，CDCl₃)8.0(s，1H)，7.47-7.36(m，2H)，7.18(d，J＝3.14Hz，IH)，6.58(d，J＝3.0Hz，1H)，4.02(d，J＝7.29Hz，2H)，3.98(d，J＝3.38Hz，2H)，3.38-3.28(m，2H)，2.10-2.05(m，1H)，1.51-1.40(m，4H)，

LC-MS m/z (M): a calculated value 240; found (M + H): 241

Synthesis of 3- ((2, 2-dimethyl-4, 6-dioxo-1, 3-dioxan-5-yl) (m-tolyl) methyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-5-carbonitrile:

to a stirred solution of 1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-5-carbonitrile (2.2g, 9.166mmol) in dry acetonitrile (20mL) was added Meldrum's acid (2.63g, 18.33mmol), m-tolualdehyde (1.4mL, 11.91mmol) and DL-proline (105.3mg, 0.916mmol) and the reaction mixture was stirred at room temperature for 16H. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated in vacuo and the crude product was used in the next step without purification (crude wt 5.6 g).

LC-MS m/z (M): calculated value 486.5; found (M + H): 487.3

Synthesis of ethyl 3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propionate:

to a stirred solution of 3- ((2, 2-dimethyl-4, 6-dioxo-1, 3-dioxan-5-yl) (m-tolyl) methyl) -1- (tetrahydro-2H-pyran-4-yl) methyl) -1H-indole-5-carbonitrile (5.6g, 11.5mmol) in a 1: 1 mixture of pyridine and ethanol (60mL) was added Cu powder (147mg, 2.30mmol) and the reaction mixture was stirred at 90 ℃ for 16H. The progress of the reaction was monitored by TLC. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 60-120 mesh, eluting with 10% EtOAc in petroleum ether) to afford the desired product as a yellow solid (yield: 950mg, 25%).

¹H NMR(400MHz，CDCl₃)7.41(d，J＝7.92Hz，1H)，7.31(d，J＝8.25Hz，1H)，7.17-7.05(m，5H)，7.01-6.9(m，2H)，4.74(t，J＝7.91Hz，1H)，4.20-4.12(m，1H)，4.04-3.95(m，2H)，3.10-3.05(m，1H)，2.28(s，3H)，2.15-2.10(m，2H)，1.94-1.90(m，2H)，1-80-1.62(m，3H)，1.50-1.41(m，2H)，1.32-1.24(m，5H)，1.26(t，J＝3.5Hz，3H)，

LC-MS m/z (M): calculated value 430.54; found (M + H): 430.9

Synthesis of 3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid:

to ethyl 3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propionate (400mg, 0.930mmol) in THF/MeOH/H at 0 deg.C₂LiOH. H was added to a stirred solution of O (1: 1) (12mL)₂O (390mg, 9.30mmol) and the reaction mixture was stirred at room temperature for 7 h. The progress of the reaction was monitored by TLC. The reaction mixture was acidified to pH 6 with citric acid, extracted with EtOAc and the separated organic layer was Na filtered₂SO₄Dried and concentrated under reduced pressure. The crude compound was purified by column chromatography, eluting with 80% EtOAc in hexanes to provide a light cream solid (yield: 300mg, 80%).

¹H NMR(400MHz，CDCl₃)7.71(s，1H)，7.40-7.28(m，2H)，7.17(t，J＝7.47Hz，1H)，7.09-7.04(m，4H)，4.70(t，J＝7.81Hz，1H)，4.01-3.92(m，4H)，3.35-3.28(m，2H)，3.12-3.0(m，2H)，2.30(s，3H)，2.09-2.0(m，1H)，1.5-1.25(m，5H)，

LC-MS m/z (M): calculated value 402.49; found (M-H): 401.1

Synthesis of tert-butyl ((1S, 4S) -4- (3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propylamino) cyclohexyl) carbamate:

to a stirred solution of 3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid (350mg, 0.870mmol) in DMF (3mL) at 0 ℃ was added DIPEA (0.32mL, 1.305mmol), HATU (495mg, 1.305mmol) followed by tert-butyl ((1s, 4s) -4-aminocyclohexyl) carbamate (242.5mg, 1.131mmol) and the reaction mixture was stirred at room temperature for 2H. The progress of the reaction was monitored by TLC. Ice cold water was added to the reaction mixture at 0 ℃ with EtOAc, extracting. The combined organic layers were passed over Na₂SO₄Dried and concentrated under reduced pressure. The crude compound was purified by column chromatography eluting with 70% EtOAc in petroleum ether to afford the desired product as an off-white solid (yield: 500mg, 96%).

¹H NMR(400MHz，DMSO-d6)7.71(s，1H)，7.39(d，J＝8.59Hz，1H)，7.31(d，J＝8.59Hz，1H)，7.18(t，J＝7.42Hz，1H)，7.10(d，J＝5.87Hz，2H)，7.04(d，J＝7.53Hz，2H)，4.66(t，J＝7.7Hz，1H)，4.28(d，J＝7.04Hz，1H)，4.0-3.95(m，4H)，3.80-3.71(m，2H)，3.45(brs，1H)，3.35-3.30(m，2H)，2.90-2.80(m，2H)，2.30(s，3H)，2.05-2.0(m，2H)，1.52-1.40(m，21H)，

LC-MS m/z (M): calculated value 598.7; found (M-Boc): 499.2

Synthesis of tert-butyl ((1S, 4S) -4- ((3- (5- (aminomethyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propyl) amino) cyclohexyl) carbamate:

to a stirred solution of tert-butyl ((1S, 4S) -4- (3- (5-cyano-1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (M-tolyl) propylamino) cyclohexyl) carbamate (300mg, 0.501) in dry THF (6mL) at 0 deg.C was added BH in THF (1M, 10mL, 10.00mmol))₃And the reaction mixture was refluxed for 8 h. The progress of the reaction was monitored by TLC. After 8h of reflux, 5mL MeOH were added, followed by 5h of reflux. The solvent was removed from the reaction mixture under reduced pressure and the crude compound was used directly in the next step without further purification (crude wt: 450 mg).

Synthesis of tert-butyl ((1S, 4S) -4- ((tert-butoxycarbonyl) amino) cyclohexyl) (3- (5- (((tert-butoxycarbonyl) amino) methyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propyl) carbamate:

to a stirred solution of tert-butyl ((1S, 4S) -4- ((3- (5- (aminomethyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propyl) amino) cyclohexyl) carbamate (450mg, 0.765mmol) was added TEA (0.55mL, 3.825mmol) followed by Boc anhydride (0.66mL, 3.061mmol) and the reaction mixture was stirred at room temperature for 12H. The progress of the reaction was monitored by TLC. The excess solvent was removed from the reaction mixture and the crude compound was purified by column chromatography using 20% EtOAc in hexanes as eluent to afford the desired compound as a brown liquid (yield: 120mg, 30%).

¹H NMR(400MHz，DMSO-d6)7.35(d，J＝8.7Hz，1H)，7.30-7.25(m，2H)，7.24-7.20(m，3H)，7.0-6.0(m，2H)，4.10-4.05(m，2H)，4.04-3.99(m，3H)，3.80-3.65(m，4H)，3.21-3.05(m，3H)，3.0-2.91(m，1H)，2.21(s，3H)，2.02-1.95(m，1H)，1.69-1.60(m，2H)，1.51-1.42(m，5H)，1.42-1.30(m，22H)，1.30-1.20(m，8H)，

LC-MS m/z (M): calculating a value of 789; found (M-Boc): 689

Synthesis of (1S, 4S) -N1- (3- (5- (aminomethyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine:

to a stirred solution of ((1s, 4s) -4- ((tert-butoxycarbonyl) amino) cyclohexyl) (3- (5- (((tert-butoxycarbonyl) amino) methyl) -1- ((tetrahydro-2H-pyran-4-yl) methyl) -1H-indol-3-yl) -3- (M-tolyl) propyl) carbamic acid tert-butyl ester (120mg, 0.152) in DCM (1.2mL) at 0 ℃ was added 4M HCl in 1, 4-dioxane (1.2mL) and the reaction mixture was stirred at room temperature for 10H. The progress of the reaction was monitored by TLC. The excess solvent was removed under reduced pressure and washed with diethyl ether to give an off-white solid (yield: 80mg, 94%). MP: 130-134 deg.C

¹H NMR(400MHz，DMSO-d6)9.28(brs，1H)，9.17(brs，1H)，8.96(brs，2H)，8.30(brs，3H)，8.12(brs，1H)，7.66(s，1H)，7.51(d，J＝8.47Hz，1H)，7.46(s，1H)，7.21(d，J＝8.47Hz，1H)，7.18-7.14(m，3H)，6.97(d，J＝5.88Hz，1H)，4.23-4.19(m，1H)，4.10-4.01(m，4H)，3.79(d，J＝10.73Hz，2H)，3.21-3.10(m，4H)，2.95-2.84(m，2H)，2.72-2.65(m，1H)，2.40-2.38(m，1H)，2.24(s，3H)，2.10-1.98(m，3H)，1.90-1.60(m，6H)，1.85-1.20(m，4H)

LC-MS m/z (M): calculated 488.3; found (M + H): 489.3

The compounds of table 2 were prepared following the procedure described in scheme 2/example II by using the appropriate starting materials and the appropriate conditions.

TABLE 2

TABLE 2

TABLE 2

General scheme 3 (FIG. 7) illustrates a synthetic route to synthesize compounds having formulas F-III and III. Reductive amination of III-a with a ketone gives III-b, which is oxidized with DDQ to afford the indole derivative III-c. Mixing Meldrum's acid and appropriate aldehyde R₂Coupling of-CHO with III-c gives the compound III-d, which under decarboxylation affords the corresponding ester III-e. III-e with the appropriate boronic acid R₅-B(OH)₂Suzuki coupling was performed to give compound III-f, followed by reduction of the ester group to give the corresponding alcohol III-g. Obtaining a compound having formula III-h from III-g by nucleophilic reaction with MsCl, the compound having formula III-h Compounds with appropriate NHR₃R₄Nucleophilic substitution is carried out to obtain III-j. Finally, deprotection of the protecting group under acidic conditions provides a salt of compound III. If R is₃And R₄Containing N and O protecting groups, which can be deprotected under various conditions reported in the literature to obtain the final compounds of formulae F-III or III listed in Table 3.

Example 3: synthesis of (1R, 4R) -N1- (3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine dihydrochloride

Step 1: 5-bromo-1-cyclohexylindoline

To a stirred solution of 5-bromoindoline (10g, 50.48mmol, compound-1) in EDC (200mL) at room temperature was added cyclohexanone (15.8m 1-cyclohexyl-1H-indole-5-carbonitrile L, 151.46 mmol). After stirring the reaction mixture for 1h, NaBH (OAc) is added₃(53.5g, 252.41 mmol) and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was washed with NaHCO₃The solution (100mL) was diluted and extracted with ethyl acetate (2 × 200 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 60-120 mesh, eluting with 2% EtOAc in petroleum ether) to afford 5-bromo-1-cyclohexylindoline (13.2g, yield: 92%) as a light yellow liquid.

1H NMR(400MHz，CDCl₃)1.10-1.17(m，1H)，1.30-1.39(m，4H)，1.68(d，J＝12.7Hz，1H)，1.76-1.84(m，4H)，2.90(t，J＝8.4Hz，2H)，3.23-3.39(m，1H)，3.36(t，J＝8.4Hz，2H)，6.22-6.24(m，1H)，7.08-7.09(m，2H)

Step 2: 5-bromo-1-cyclohexyl-1H-indoles

To a stirred solution of 5-bromo-1-cyclohexylindoline (13g, 46.55mmol) in dry THF (130mL) at 0 deg.C was added DDQ (11.6g, 51.21mmol) and the reaction mixture was stirred at the same temperature for 5 min. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (20mL) and extracted with ethyl acetate (2X 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 60-120 mesh, eluting with 2% EtOAc in petroleum ether) to afford 5-bromo-1-cyclohexyl-1H-indole (10g, yield: 77%) as a pale green liquid.

Step 3: 5- ((5-bromo-1-cyclohexyl-1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione

To a solution of 5-bromo-1-cyclohexyl-1H-indole (5g, 17.985mmol) in CH₃To a stirred solution in CN (50mL) was added m-tolualdehyde (3.1mL, 26.97mmol), DL-proline (207mg, 1.798mmol) followed by Meldrum's acid (5.1g, 35.971mmol) and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to give 5- ((5-bromo-1-cyclohexyl-1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione as a brown semisolid (13g, crude). The crude compound was used in the next step.

LC-MS m/z(M-H)：429.4

And 4, step 4: 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionic acid ethyl ester

To a stirred solution of 5- ((5-bromo-1-cyclohexyl-1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione (13g, 24.787mmol) in EtOH/pyridine (195mL, 1: 1v/v) was added Cu powder (143mg, 2.478mmol) and the reaction mixture was stirred at 90 ℃ ″. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, filtered and the filtrate was concentrated under reduced pressure. The crude compound was purified by combi-flash column chromatography eluting with 10% EtOAc in petroleum ether to afford ethyl 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionate as a pale yellow semi-solid (7g, yield: 60%).

1H NMR(400MHz，CDCl₃)1.10(t，J＝2.1Hz，3H)，1.22-1.33(m，1H)，1.42-1.53(m，2H)，1.61-1.71(m，2H)，1.78(d，J＝13.1Hz，1H)，1.92(d，J＝13.3Hz，2H)，2.08(s，2H)，2.30(s，3H)，2.93-2.99(m，1H)，3.03-3.09(m，1H)，4.00-4.09(m，2H)，4.10-4.15(m，1H)，4.67(t，J＝7.9Hz，1H)，6.99(d，J＝7.3Hz，1H)，7.06-7.08(m，3H)，7.13-7.20(m，3H)，7.53(d，J＝1.5Hz，1H)

LC-MS m/z(M+H)：468.4

And 5: 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionic acid ethyl ester

To ethyl 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionate (500mg, 1.068mmol) in dioxane/H at room temperature₂(1-methyl-1H-pyrazol-5-yl) boronic acid (161mg, 1.282mmol) and Na were added to a stirred solution of O (10mL, 4: 1v/v)₂CO₃(339mg, 3.205 mmol). Degassing for 10min, and adding Pd (PPh)₃)₄(123mg, 0.106mmol), degassed again for 5min and the reaction mixture stirred in the microwave for 1h at 120 ℃. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through a celite pad, and the filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by combi-flash column chromatography eluting with 13% EtOAc in petroleum ether to afford ethyl 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionate as a pale yellow semi-solid (300mg, yield: 33%).

LC-MS m/z(M+H)：470.3

Step 6: 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propan-1-ol

To a stirred solution of ethyl 3- (5-bromo-1-cyclohexyl-1H-indol-3-yl) -3- (m-tolyl) propionate (300mg, 0.639mmol) in THF (6mL) at 0 ℃ was added LAH (48mg, 1.279mmol) and the reaction mixture was stirred at room temperature for 1H. The progress of the reaction was monitored by TLC. The reaction mixture was slowly poured over Na₂SO₄To the paste, filtration was carried out, and the filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propan-1-ol as a pale yellow semisolid (250mg, yield: 91%).

LC-MS m/z(M+H)：428.3

And 7: 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl methanesulfonate

To 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propan-1-ol (250mg, 0.585mmol) in CH at 0 deg.C₂Cl₂To a stirred solution in (5mL) was added TEA (0.2mL, 1.463mmol) followed by MsCl (0.07mL, 0.877mmol) and the reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (10mL) and extracted with DCM (2 × 10 mL). The combined organic layers were washed with NaHCO₃The solution was washed, dried over anhydrous sodium sulfate, and filtered under reduced pressure to give 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl methanesulfonate (340mg, crude) as a yellow semi-solid. The crude compound was used in the next step.

And 8: ((1R, 4R) -4- ((3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) amino) cyclohexyl) carbamic acid tert-butyl ester

To a stirred solution of 3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propylmethanesulfonate (340mg, 0.672mmol) in DMF (5mL) was added tert-butyl ((1R, 4R) -4-aminocyclohexyl) carbamate (216mg, 1.008mmol) followed by K₂CO₃(278mg, 2.017mmol) and the reaction mixture was stirred at 80 ℃ for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with water (10mL), filtered, and the residue was dissolved in ethyl acetate (20mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was passed through preparative TLC (5% MeOH/CH)₂Cl₂) Purification was performed to provide tert-butyl ((1R, 4R) -4- ((3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) amino) cyclohexyl) carbamate (100mg, yield: 23%).

LC-MS m/z(M+H)：624.3

And step 9: (1R, 4R) -N1- (3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) cyclohexane-1, 4-diamine dihydrochloride

To tert-butyl ((1r, 4r) -4- ((3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-tolyl) propyl) amino) cyclohexyl) carbamate (70mg, 0.113mmol) in CH₂Cl₂To a stirred solution in (2mL) HCl in dioxane (2mL) was added and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The crude compound was washed with pentane (5mL) to provide (1R, 4R) -N1- (3- (1-cyclohexyl-5- (1-methyl-1H-pyrazol-5-yl) -1H-indol-3-yl) -3- (m-methyl) as an off-white solidPhenyl) propyl) cyclohexane-1, 4-diamine dihydrochloride (16mg, yield: 23%).

1H NMR(400MHz，DMSO-d₆)1.22-1.44(m，5H)，1.46-1.56(m，2H)，1.70-1.85(m，5H)，1.95-2.06(m，6H)，2.24(s，3H)，2.31(s，1H)，2.79(s，1H)，2.92(s，3H)，3.79(s，4H)，4.31-4.37(m，2H)，6.96(s，1H)，7.13-7.18(m，4H)，7.41(d，J＝1.5Hz，1H)，7.49(s，1H)，7.57(d，J＝8.5Hz，1H)，7.61(s，1H)，7.99(s，3H)，9.03(s，1H)，9.14(s，1H)

LC-MS m/z(M+H)：524.3

The compounds of table 3 were prepared following the procedure described in scheme 3/example III by using the appropriate starting materials and the appropriate conditions.

TABLE 3

General scheme 4 (figure 8) shows the synthesis of compounds having formula IV. IV-a with various boric acids or esters (like R)₅-B(ＯH)₂) Coupling of Suzuki to give the compound of formula IV-b, giving the corresponding ketone IV-c under a Lewis acid in a Michael reaction. The reductive amination of IV-c gives the corresponding amine IV-d. If R is₃、R₄Containing a protecting group, deprotection is carried out under acidic conditions to provide a salt of compound IV.

Example 4: synthesis of (3- ((2- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl-1H-indol-3-yl) ethyl) amino) propyl) carbamate dihydrochloride

Synthesis of 1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indole:

to a stirred solution of 5-bromo-1-cyclohexyl-1H-indole (3g, 10.791mmol) in DME (39mL) under a nitrogen atmosphere was added Pd (PPh)₃)₄(623mg, 0.539mmol) and the reaction mixture was stirred at room temperature for 15 min. After 15min, a solution of (3- (trifluoromethoxy) phenyl) boronic acid (2.22g, 10.791mmol) in EtOH (10mL) was added to the reaction mixture and stirred again at room temperature for 15 min. Finally, Na is added₂CO₃(2M) aqueous solution (39mL) and the reaction mixture was stirred at 90 ℃ for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, filtered through a bed of celite, and the filtrate was extracted with EtOAc (3 × 50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography using 2% EtOAc in petroleum ether as eluent to afford the desired product as a colorless liquid (yield: 1.19g, 30.7%).

¹H NMR(400MHz，CDCl₃)7.82(s，1H)，7.63-7.55(m，1H)，7.50-7.38(m，3H)，7.29-7.26(m，1H)，7.25-7.18(m，1H)，7.16-7.08(m，1H)，4.28-4.20(m，1H)，2.20-2.10(m，2H)，2.00-1.90(m，2H)，1.85-1.68(m，3H)，1.52-1.46(m，2H)，1.38-1.22(m，1H)

LC-MS m/z (M): calculated value 359.3; found (M + H): 360.17

Synthesis of 3- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indol-3-yl) cyclohexanone:

to a stirred solution of 1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indole (1.19g, 3.311mmol) in dry ACN (12mL) at 0 deg.C was added cyclohex-2-enone (0.32mL, 3.311mmol) followed by ZrCl₄And the reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture turned blue and the progress of the reaction was monitored by TLC. The reaction mixture was diluted with water, extracted with EtOAc, dried over sodium sulfate, and reduced pressureAnd (5) concentrating. The crude compound was purified by column chromatography using 6% EtOAc in petroleum ether as eluent to afford the desired product as a brown liquid (yield: 238mg, 15.8%).

¹H NMR(400MHz，CDCl₃)7.75(s，1H)，7.58-7.55(m，1H)，7.48-7.42(m，3H)，7.20-7.15(m，1H)，7.04(s，1H)，7.02-6.98(m，1H)，4.24-4.18(m，1H)，3.52-3.48(m，1H)，2.82-2.78(m，1H)，2.68-2.60(m，1H)，2.49-2.40(m，2H)，2.39-2.32(m，1H)，2.30-2.22(m，1H)，2.15-2.10(m，2H)，2.05-1.90(m，4H)，1.88-1.78(m，2H)，1.75-1.68(m，2H)，1.55-1.45(m，2H)，1.35-1.20(m，5H)，0.90-0.80(m，2H)

LC-MS m/z (M): calculated value 455.51; found (M + H): 456.2

Synthesis of tert-butyl (3- ((3- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indol-3-yl) cyclohexyl) amino) propyl) carbamate:

to a stirred solution of 3- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indol-3-yl) cyclohexanone (120mg, 0.263mmol) in MeOH (3mL) was added tert-butyl (3-aminopropyl) carbamate (59.6mg, 0.342mmol), AcOH (36.2mg, 0.604mmol) and the reaction mixture was stirred at room temperature for 1H, after which NaCNBH was added at 0 deg.C₄(33mg, 0.526) the reaction mixture was then stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was washed with NaHCO₃Aqueous solution (10mL) was diluted and the compound was extracted with 10% MeOH in DCM (3 × 10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was purified by preparative HPLC method to provide the desired product as colorless viscous material (yield: 30mg, 18.6%).

¹H NMR(400MHz，CDCl₃)7.81(s，1H)，7.72-7.68(m，1H)，7.60-7.52(m，3H)，7.40(d，J＝8.71Hz，1H)，7.30-7.22(m，2H)，6.82-6.78(m，1H)，4.32-4.28(m，1H)，3.02-2.88(m，3H)，2.60-2.55(m，2H)，2.20-2.18(m，1H)，2.0-1.90(m，4H)，1.88-1.78(m，3H)，1.75-1.68(m，3H)，1.15-1.45(m，5H)，1.38-1.36(m，1H)，1.32(s，9H)，1.25-1.20(m，6H)

LC-MS m/z (M): calculated value 613.7; found (M + H): 614.23

Synthesis of (3- ((2- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl-1H-indol-3-yl) ethyl) amino) propyl) carbamate dihydrochloride:

to tert-butyl (3- ((3- (1-cyclohexyl-5- (3- (trifluoromethoxy) phenyl) -1H-indol-3-yl) cyclohexyl) amino) propyl) carbamate (30mg, 0.048mmol) in CH at 0 deg.C₂Cl₂To a stirred solution in (1mL) HCl in dioxane (4M, 1mL) was added and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure and the crude compound was washed with n-pentane to provide the desired compound as an off-white solid (yield: 25mg, 87%).

MP：202℃-206℃

¹H NMR(400MHz，DMS0-d6)9.05-9.02(m，2H)，8.80-8.74(m，2H)，7.89-7.88(m，1H)，7.74(d，J＝7.88Hz，1H)，7.61-7.45(m，3H)，7.44(d，J＝8.36Hz，1H)，7.30-7.28(m，2H)，4.33(t，J＝11.56Hz，1H)，3.59-3.52(m，2H)，2.42-2.38(m，1H)，2.25-2.10(m，3H)，2.0-1.90(m，4H)，1.89-1.80(m，5H)，1.75-1.62(m，3H)，1.60-1.40(m，6H)，1.32-1.30(m，1H)，

LC-MS m/z (M): calculated value 513.6; found (M + H): 514.33

The compounds of table 4 were prepared following the procedure described in scheme 4/example IV by using the appropriate starting materials and the appropriate conditions.

TABLE 4

The synthetic route to compound V is depicted in general scheme 5A (fig. 9). With R₂The condensation reaction of CHO and cyclic esters with indole derivatives gives VA-b, which under decarboxylation Cu-EtOH gives ester derivatives VA-d. The ester is saponified and coupled with an amine to give the amide derivative VA-f. If compound VA-f contains any protecting group as VA-g, the final compound V is obtained by deprotection under acidic conditions to give an acidic salt of the free base.

Example 5A: synthesis of 3- (1-benzyl-1H-indol-3-yl) -N- (2- (piperidin-4-yl) ethyl) -3- (m-tolyl) propionamide hydrochloride

Synthesis of 5- ((1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione

Indole (2.0g, 17.1mmol), Meldrum's acid (3.03g, 21.0mmol), m-tolualdehyde (4.1g, 34.2mmol) and DL-proline (100mg) in CH₃The mixture in CN (25mL) was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo and the crude product was used in the next step without purification.

Synthesis of ethyl 3- (1H-indol-3-yl) -3- (m-tolyl) propionate:

to the crude product (4.6g, 12.6mmol) from the previous step in a 1: 1 mixture of pyridine and EtOH (60mL) was added Cu powder (80mg, 1.26 mmol). The reaction mixture was heated to reflux for 16 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue is chromatographed on a column (silica gel, ethyl acetate +)Hexane) to afford a red oil (2.15g, 54%). ESI MS M/z 308[ M + H ]]⁺。

Synthesis of ethyl 3- (1-benzyl-1H-indol-3-yl) -3- (m-tolyl) propionate:

at 0 ℃ to (1.0g, 3.45mmol) and CS₂CO₃(1.70g, 5.18mmol) to a mixture in DMF (10mL) was added benzyl bromide (0.5mL, 3.80 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction was quenched by the addition of ice water (10mL) followed by extraction with EtOAc (2X 25 mL). The organic layers were combined and dried over anhydrous MgSO₄Dried and concentrated under reduced pressure, and the crude material was purified by column chromatography (silica gel, EtOAc/hexanes) to afford intermediate (320mg, 32%) as a yellow oil. ESI MS M/z 398[ M + H ]]⁺。

Synthesis of 3- (1-benzyl-1H-indol-3-yl) -3- (m-tolyl) propionic acid:

to the solution (320mg 0.8mmol) in THF/MeOH/H₂To a solution of O (6mL) in the mixture was added LiOH (192mg, 8 mmol). The reaction mixture was stirred at room temperature for 8h and concentrated in vacuo. Dissolving the residue in H₂O (5mL) and pH adjusted to 6.0 using 1N HCl, and the aqueous layer extracted with EtOAc (2X 20 mL). The organic layers were combined and dried over anhydrous MgSO₄Dried and concentrated under reduced pressure to afford intermediate (254mg, 85%) as an off-white solid. ESI MS M/z 370[ M + H ]]⁺。

Synthesis of tert-butyl 4- (2- (3- (1-benzyl-1H-indol-3-yl) -3- (m-tolyl) propylamino) -ethyl) piperidine-1-carboxylate:

to a mixture of (48mg, 0.13mmol) in DMF (1.5mL)To the mixture were added HATU (69mg, 0.18mmol), DIPEA (45uL, 0.26mmol) and tert-butyl 4- (2-aminoethyl) piperidine-1-carboxylate (35mg, 0.15 mmol). The reaction mixture was stirred at room temperature for 16h and purified by reverse phase column chromatography to afford intermediate (33mg, 44%) as a white solid. ESI MS M/z 580[ M + H ]]⁺。

Synthesis of 3- (1-benzyl-1H-indol-3-yl) -N- (2- (piperidin-4-yl) ethyl) -3- (m-tolyl) propionamide hydrochloride

To a solution of (30mg, 0.052mmol) in MeOH (2mL) was added HCl in dioxane (4M, 1 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and the residue was lyophilized to afford the product as a red-brown semi-solid (25mg, 70%).¹H NMR(400MHz，DMS0-d₆)8.49(bs, 1H), 8.21(bs, 1H), 7.81(t, J ═ 5.74Hz, 1H), 7.43(bs, 1H), 7.36(d, J ═ 8.61Hz, 2H), 7.32-7.23(m, 3H), 7.19-7.15(m, 2H), 7.13-7.08(m, 3H), 7.03(t, J ═ 7.76Hz, 1H), 6.95-6.88(m, 2H), 5.37(bs, 2H), 4.64(t, J ═ 7.98Hz, 1H), 3.19-2.98(m, 4H), 2.95-2.83(m, 2H), 2.74(dd, J ═ 14.0, 8.10, 1H), 2.61-2.55(m, 1H), 2.23, 1H, 5.55H, 1H), 1.5.5.5.7 (m, 2H); HPLC (method 6) 96.4% (AUC), t_R＝19.83min，ESI MS m/z 480[M+H]⁺。

The synthetic route to compound VB is depicted in general scheme 5B (fig. 10). The indole was N-alkylated with a suitable alkyl halide to give the compound VB-a which was condensed with Meldrum's acid and the appropriate aldehyde to give the compound VB-b, followed by decarboxylation at Cu-Et0H to give the ester derivative VB-c. The ester was saponified and coupled with an amine to give the amide derivative VB-e. If compound VA-f contains any protecting groups, the final compound V is obtained by deprotection under acidic conditions to give an acidic salt of the free base.

Example 5B: synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propanamide

Synthesis of 1- (cyclohexylmethyl) -1H-indole:

to a slurry of NaH (2.0g, 0.51mmol) in DMF (25mL) at 0 deg.C was added indole (4.0g, 34.0 mmol). (bromomethyl) cyclohexane (9.8g, 0.51mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The reaction was quenched by addition of water (15mL) and then extracted with EtOAc (2X30 mL). The EtOAc layer was dried (Na)₂SO₄) The residue was concentrated and purified by column chromatography (silica gel, EtOAc/hexanes) to afford 1- (cyclohexylmethyl) -1H-indole (6.3g, 86% yield) as a white viscous solid. ESI MS M/z 214[ M + H ]]⁺。

Synthesis of 5- ((1- (cyclohexylmethyl) -1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione

Preparation of 5- ((1- (cyclohexylmethyl) -1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione by the procedure described for the synthesis of intermediates: stirring at room temperature (1.0 equiv.), m-tolualdehyde (1.3 equiv.), Meldrum's acid (2.0 equiv.) and DL-proline (0.1 equiv.) in CH₃Solution in CN 16 h. The crude 5- ((1- (cyclohexylmethyl) -1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione was used directly in the next step. ESI MS M/z 460[ M + H ]]⁺。

Synthesis of ethyl 3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propionate

Ethyl 3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propanoate was prepared by heating a solution of 5- ((1- (cyclohexylmethyl) -1H-indol-3-yl) (m-tolyl) methyl) -2, 2-dimethyl-1, 3-dioxane-4, 6-dione (1.0 equiv.) and Cu powder (0.1 equiv.) in a mixture of pyridine/EtOH at 90 ℃ for 16H by the procedure described for the synthesis of intermediates 1-5. Obtained as a brown oil (58% yield).

Synthesis of 3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid:

by 3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid ethyl ester (1.0 equiv.) and LiOH (10.0 equiv.) in THF/MeOH/H₂A solution of a mixture of O (1: 1) was subjected to ester hydrolysis at room temperature for 4-6H to prepare 3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propionic acid. An off-white solid was obtained (90% yield).

General procedure for the synthesis of amides:

to a mixture of 8(1.0 eq) HATU (1.5 eq) and DIPEA (2.0 eq) in DMF (1mL) was added the corresponding amine (1.3 eq). The reaction mixture was stirred at room temperature for 16h and purified by reverse phase C18 column chromatography or precipitated by addition of water to afford the amide intermediate.

General procedure for deprotection of BOC group:

the amide intermediate with Boc group was Boc deprotected by adding HCl in dioxane to a solution of the amide intermediate in MeOH. The reaction mixture is then concentrated in vacuo and the residue is taken up in a solvent (e.g. EtOAc or CH)₃CN) and then lyophilized. By addition of an intermediate to H₂Suspension in O was converted to the corresponding hydrochloride salt by addition of 1M HCl followed by lyophilization of those intermediates having basic nitrogen.

Synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -3- (1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propanamide

¹H NMR (400MHz, methanol-d)₄)7.30(t, J ═ 8.8Hz, 2H), 7.14 to 7.04(m, 5H), 6.96(t, J ═ 7.5Hz, 1H), 6.91 to 6.86(m, 1H), 4.69(t, J ═ 8.1Hz, 1H), 3.96(d, J ═ 7.2Hz, 2H), 3.04 to 2.92(m, 2H), 2.84 to 2.75(m, 1H), 2.25(s, 3H), 2.00 to 1.91(m, 2H), 1.90 to 1.81(m, 1H), 1.80 to 1.65(m, 5H), 1.64 to 1.54(m, 2H), 1.45 to 1.32(m, 2H), 1.27 to 1.17(m, 4H), 1.16 to 0.95(m, 4H; HPLC (method 5) 93.6% (AUC), t_R＝12.28min；ESI-MS m/z 472[M+H]⁺。

The compounds of table 5 were prepared following the procedure described in schemes 5A & 5B/examples VA & VB by using the appropriate starting materials and the appropriate conditions.

TABLE 5

TABLE 5

TABLE 5

TABLE 5

TABLE 5

TABLE 5

TABLE 5

Compound VI-a was synthesized following the procedure followed in scheme 5B, starting with 5-Br indole, followed by coupling with the appropriate boronic acid, followed by deprotection to afford compound VI (general scheme 6, fig. 11).

Example VI: synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -3- (1- (cyclohexylmethyl) -5-phenyl-1H-indol-3-yl) -3- (m-tolyl) propanamide

See fig. 12.

Pd (PPh)₃)₄(5.3mg, 0.0046mmol), sodium carbonate (14.49mg, 0.138mmol), phenylboronic acid (6.67, 0.552mmol) and tert-butyl ((1R, 4R) -4- (3- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) -3- (m-tolyl) propylamino) cyclohexyl) carbamate (30mg, 0.046mmol) were added to 2mL of a degassed mixture of 1, 4-dioxane and water (8: 2). The reaction was heated in a microwave oven at 120 ℃ for 1 h. The reaction mixture was diluted with EtOAc (25mL) and washed with H₂O (30ml X2) wash. The EtOAc layer was dried (Na)₂SO₄) Concentrated in vacuo and the residue was purified by combi-flash chromatography (silica gel, ethyl acetate/hexane) to afford tert-butyl ((1R, 4R) -4- (3- (1- (cyclohexylmethyl) -5-phenyl-1H-indol-3-yl) -3- (m-tolyl) propylamino) cyclohexyl) carbamate (17mg, 33%) as a white solid. APCI MS M/z 648[ M + H ]]⁺. It was deprotected under acidic conditions to obtain the title compound.

¹H NMR(400MHz，DMSO-d₆)7.80(bs，4H)，7.55-7.50(m，3H)，7.47(d，J＝7.4Hz，1H)，7.41(t，J＝7.4Hz，2H)，7.37-7.32(m，1H)，7.30-7.23(m，2H)，7.14-7.03(m，3H)，6.94-6.87(m，1H)，4.68(t，J＝7.9Hz，1H)，3.98(d，J＝7.2Hz，2H)，3.70-3.53(m，1H)，3.40-3.32(m，1H)，3.16-3.06(m，1H)，2.99-2.79(m，2H)，2.76-2.61(m，1H)，2.21(s，3H)，1.89-1.81(m，2H)，1.69-1.60(m，4H)，1.56-1.50(m, 1H), 1.30-1.23(m, 7H), 1.17-1.07(m, 3H). HPLC (method 5) 98.1% (AUC), t_R＝13.31min；ESI-MS m/z 548.6[M+H]⁺。

Following the procedure described in scheme 6/example VI, the compounds of table 6 were prepared by using the appropriate starting materials and the appropriate conditions.

TABLE 6

General scheme 8 (fig. 13) illustrates the synthesis of compound VIII. Reductive amination of VIII-a with the appropriate aldehyde RCHO gives VIII-b, which undergoes N-deprotection under acidic conditions and yields the salt of compound VIII.

Example VIII: synthesis of 2- (1H-indol-3-yl) -N- (3-phenoxybenzyl) ethan-1-amine

General procedure for reductive amination:

a mixture of tryptamine (1.0 eq) and the corresponding aldehyde (1.05 eq) was stirred at room temperature for 1 h. The reaction mixture was then cooled to 0 ℃ and NaBH was added₄(1.2 equiv.). The reaction mixture was stirred at room temperature for 2-16 h. After completion, the reaction mixture was cooled to 0 ℃ by dropwise addition of H₂Quenching with CH₂Cl₂And (4) extracting. Will CH₂Cl₂Layer drying (Na)₂SO₄) Concentrated and the residue purified by column chromatography (silica gel, EtOAc/hexanes) to afford intermediate VIII-b.

General procedure for Boc deprotection/HCl salt formation:

the intermediate with Boc group was Boc deprotected by adding HCl in dioxane to a solution of the intermediate in MeOH. The reaction mixture is then concentrated in vacuo and the residue is taken up in a solvent (e.g. EtOAc or CH)₃CN) and then lyophilized. Those intermediates having basic nitrogen are converted to the corresponding hydrochloride salts.

Following the procedure described in scheme 8/example VIII, the compounds of table 8 were prepared by using the appropriate starting materials and the appropriate conditions.

TABLE 8

TABLE 8

TABLE 8

General scheme 9 (fig. 14) demonstrates a synthetic route to compound IX. Esterification of IX-a and subsequent alkylation of IX-b provides the ester IX-c. Ester hydrolysis of IX-c and subsequent coupling reaction with a suitable amine affords compound IX-e. Suzuki coupling of IX-e with boronic acid was performed to afford compound IX-f, which was deprotected under acidic conditions and yielded a salt of compound IX.

Example IX: synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -2- (1- (cyclohexylmethyl) -5- (m-tolyl) -1H-indol-3-yl) acetamide hydrochloride.

Synthesis of methyl 2- (5-bromo-1H-indol-3-yl) acetate:

a solution of 2- (5-bromo-1H-indol-3-yl) acetic acid (500mg, 1.97mmol) in anhydrous MeOH (100mL) was treated with PTSA (34mg, 0.197mmol) andheating at 75 deg.C for 16 h. The mixture was concentrated and the residue was dissolved in CH₂Cl₂(50mL), washed with water (3X 20mL) and brine (20 mL). Will CH₂Cl₂Layer separation and drying (Na)₂SO₄) Filtered and concentrated to give methyl 2- (5-bromo-1H-indol-3-yl) acetate as a dark red solid (465mg, 88%). ESI-MS M/z 268[ M ]]⁺。

Synthesis of methyl 2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetate:

to a slurry of cesium carbonate (486mg, 1.49mmol) in DMF (3mL) at 0 deg.C was added a solution of methyl 2- (5-bromo-1H-indol-3-yl) acetate (200mg, 0.746mmol) in DMF (10mL), followed by bromomethylcyclohexane (0.156mL, 1.12 mmol). The reaction mixture was slowly warmed to room temperature over 16 h. The reaction mixture was quenched with water, dissolved in EtOAc (50mL), washed with water (3 × 20mL) and brine (20 mL). The EtOAc layer was separated and dried (Na)₂SO₄) Filtered and concentrated. The residue was purified by combi-flash chromatography (silica gel, EtOAc/hexanes) to give methyl 2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetate (64mg, 24%) as a yellow oil. ESI-MS M/z 364[ M ]]⁺。

Synthesis of 2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetic acid:

using the procedure described for intermediates 1-7 (scheme 4), ester hydrolysis by 180-3(155mg, 0.425mmol) was performed with MeOH/THF/H₂Lithium hydroxide (102mg, 4.25mmol) in O (1: 1) prepared 2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetic acid. A yellow solid (126mg, 85%) was obtained. ESI-MS M/z 350[ M ]]⁺。

Synthesis of tert-butyl ((1R, 4R) -4- (2- (5-bromo-1- (cyclohexylmethyl) -IH-indol-3-yl) acetamido) cyclohexyl) carbamate:

coupling of 2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetic acid (86mg, 0.245mmol) with tert-butyl ((1r, 4r) -4-aminocyclohexyl) carbamate (63mg, 0.295mmol) prepared tert-butyl ((1r, 4r) -4- (2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetamido) cyclohexyl) carbamate using HATU (130mg, 0.343mmol) as coupling reagent and DIPEA (0.08mL, 0.49mmol) as base in DMF as described for the synthesis of intermediates 1-9. A yellow solid was obtained (74mg, 56%). ESI-MS M/z 546[ M]⁺。

Synthesis of tert-butyl ((1R, 4R) -4- (2- (1- (cyclohexylmethyl) -5- (m-tolyl) -1H-indol-3-yl) acetamido) cyclohexyl) carbamate:

a solution of tert-butyl ((1R, 4R) -4- (2- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) acetylamino) cyclohexyl) carbamate (80mg, 0.146mmol), m-tolylboronic acid (30mg, 0.220mmol), cesium carbonate (142mg, 0.438mmol) dissolved in 1, 4 dioxane (1.6mL) and water (0.4mL) was bubbled with argon for 10 min. Pd (dppf) (5mg, 0.007mmol) was then added to the vial and sealed. The reaction mixture was heated at 100 ℃ for 16 h. It was filtered, dissolved in EtOAc (20mL), washed with water (3X 10mL) and brine (10 mL). The Et0Ac layer was separated and dried (Na)₂SO₄) Filtered and concentrated in vacuo. The residue was dissolved in MeOH and purified by C18 reverse phase combi-flash chromatography (acetonitrile/water) to give tert-butyl ((1R, 4R) -4- (2- (1- (cyclohexylmethyl) -5- (m-tolyl) -1H-indol-3-yl) acetamido) cyclohexyl) carbamate (16mg, 20%) as a light yellow solid. ESI-MS M/z 558[ M + H ]]⁺。

Synthesis of N- ((1R, 4R) -4-aminocyclohexyl) -2- (1- (cyclohexylmethyl) -5- (m-tolyl) -1H-indol-3-yl) acetamide hydrochloride.

The title compound was prepared by deprotection of 5(30mg, 0.05mmol) of the Boc group using the procedure described previously with HCl in dioxane. Obtained as an amorphous off-white solid (6mg, 43%).¹H NMR (400MHz, methanol-d)₄)7.90(d, J ═ 7.3Hz, 1H), 7.77(s, 1H), 7.46-7.39(m, 4H), 7.28(t, J ═ 7.6Hz, 1H), 7.13-7.08(m, 2H), 3.98(d, J ═ 7.3Hz, 2H), 3.65(s, 3H), 3.07-3.01(m, 1H), 2.40(s, 3H), 2.06-1.97(m, 4H), 1.99-1.83(m, 1H), 1.79-1.71(m, 2H), 1.69-1.59(m, 3H), 1.53-1.41(m, 2H), 1.39-1.28(m, 2H), 1.27-1.17(m, 3H), 1.11-0.99(m, 2H); HPLC (method 5) 97.1% (AUC), t_R＝12.62min；ESI-MS m/z 458[M+H]⁺。

Following the procedure described in scheme 9/example IX, the compounds of table 9 were prepared by using the appropriate starting materials and the appropriate conditions.

Table 9:

table 9:

general scheme 10 (fig. 15) shows a method for preparing compound X. The appropriate azaindole (X-a), Meldrum's acid and aldehyde R₂CHO condensation gives the compound X-b, which under decarboxylation gives the ester derivative X-c. N-alkylation of X-c with a benzyl halide gives the compound X-d, followed by hydrolysis of the ester group to afford the corresponding acid X-e. With appropriate NHR under coupling conditions₃R₄Treatment of X-e gives the compound of formula X-f. Finally, the N-protecting group is reacted under suitable conditionsDeprotection of the group affords compound X.

The compounds of formula X mentioned in table 10 are prepared according to the procedure described in general scheme VA for the preparation of compound VA, starting from the appropriate azaindole/substituted indole derivative.

Watch 10

Watch 10

(1R，4R)-N¹- (4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) cyclohexane-1, 4-diamine dihydrochloride (diastereomer B-compound 265)&266) Synthesis of (2)

See general scheme 11 (fig. 16).

Synthesis of 5-bromo-3- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-indole (XI-b):

coupling 5-bromo-1H-indole (1.0g, 5.10mmol), 1, 4-dioxaspiro [4.5]]A mixture of decan-8-one (795mg, 5.10mmol) and potassium hydroxide (16g, 25.50mmol) in MeOH (10mL) was heated to reflux for 2-3 h. The reaction mixture was cooled to room temperature and water (20mL) was added to quench the reaction. The reaction mixture was extracted with EtOAc (50mL), washed with water (30mL X2) and brine (15 mL). The EtOAc layer was dried (Na)₂SO₄) Concentrated in vacuo and the residue purified by combi-flash chromatography (silica gel, EtOAc/hexanes) to afford 5-bromo-3- (1, 4-dioxaspiro [4.5] spiro as a white solid]Dec-7-en-8-yl) -1H-indole (1.50g, 87%). ESI MS M/z 334[ M + H ]]⁺。

Synthesis of 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5] dec-en-8-yl) -1H-indole (XI-c):

synthesis of said procedure Using intermediate (XI-c)By 5-bromo-3- (1, 4-dioxaspiro [4.5]]N-alkylation of dec-7-en-8-yl) -1H-indole with (bromo-methyl) cyclohexane and NaH as base preparation of 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5]]Dec-7-en-8-yl) -1H-indole. A colorless oil was obtained (70% yield). ESI MSm/z 430[ M + H ]]⁺。

Synthesis of 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5] decan-8-yl) -1H-indole (XI-d):

reacting 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5]]Dec-7-en-8-yl) -1H-indole (450mg) (5) was dissolved in 10ml of EtOAc and 5mg of platinum oxide was added thereto. The reaction mixture was shaken in a Parr shaker (Parr shaker) under 35PSI of hydrogen pressure for 8 h. The reaction mixture was filtered through a celite bed and concentrated in vacuo to provide 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5] as a semi-solid]Decan-8-yl) -1H-indole (450mg), which was used as such in the next step without purification. ESI MS M/z 432[ M + H ]]⁺。

Synthesis of 4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexanone (XI-e):

reacting 5-bromo-1- (cyclohexylmethyl) -3- (1, 4-dioxaspiro [4.5]]Decan-8-yl) -1H-indole (450mg) was taken up in a mixture of 6ml THF and 6ml 1N HCl. The reaction mixture was stirred at room temperature for 14h and neutralized with a saturated solution of sodium bicarbonate. The reaction mixture was extracted with EtOAc (50mL), washed with water (30mL X2) and brine (15 mL). The EtOAc layer was dried (Na)₂SO₄) And concentrated in vacuo to afford 4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexanone (350mg, 86%) as a semi-solid. ESI MS M/z 388[ M + H ]]⁺。

Synthesis of tert-butyl ((1r, 4r) -4- ((4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) amino) cyclohexyl) carbamate (IX-f):

((1R, 4R) -4-aminocyclohexyl) carbamic acid tert-butyl ester (145mg, 0.68mmol), 4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexanone (220mg, 0.56mmol) and NaBH (OAc)₃Absorbed in 5mL of 1, 2-dichloroethane and acetic acid (0.1mL) was added. The reaction mixture was stirred at room temperature for 16h,and neutralized with a saturated solution of sodium bicarbonate. Reacting the mixture with CH₂Cl₂Extract (50mL) and wash with brine (15 mL). Separation of CH₂Cl₂Layer, drying (Na)₂SO₄) Concentrated in vacuo and the residue was purified by combi-flash chromatography (silica gel, EtOAc/hexanes) to afford tert-butyl ((1R, 4R) -4- ((4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) amino) cyclohexyl) carbamate (30mg, 9%) (as diastereomer a (XI-ga))¹H NMR(400MHz，CDCl3)7.71(d，J＝1.7Hz，1H)，7.23(dd，J＝8.6，1.8，Hz，1H)，7.21(d，J＝1.9Hz，1H)，7.13(d，J＝8.7Hz，1H)，4.36(bs，1H)，3.87(d，J＝7.8Hz，2H)，3.39(bs，1H)，3.01-2.84(m，2H)，2.58-2.42(m，1H)，2.06-1.89(m，4H)，1.86-1.75(m，5H)，1.73-1.62(m，8H)，1.61-1.55(m，2H)，1.43(s，9H)，1.29-1.06(m，7H)，1.04-0.90(m，2H)；ESI MS m/z 586[M+H]⁺And tert-butyl ((1R, 4R) -4- ((4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) amino) cyclohexyl) carbamate (20mg, 6%) as a white solid (as diastereomer B (XI-gb)).¹H NMR(400MHz，CDCl3)7.71(d，J＝1.8Hz，1H)，7.23(dd，J＝8.6，1.8Hz，1H)，7.13(d，J＝8.7Hz，1H)，6.77(s，1H)，4.36(bs，1H)，3.82(d，J＝7.2Hz，2H)，3.42(bs，1H)，2.78-2.59(m，3H)，2.14-2.05(m，3H)，2.04-1.96(m，5H)，1.94-1.87(m，3H)，1.81-1.74(m，1H)，1.72-1.64(m，3H)，1.61-1.55(m，2H)，1.53-1.48(m，1H)，1.43(s，9H)，1.34-1.30(m，1H)，1.26-1.18(m，3H)，1.17-1.09(m，4H)，1.01-0.89(m，2H)；ESI MS m/z 586[M+H]⁺。

(1R，4R)-N¹Synthesis of- (4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) cyclohexane-1, 4-diamine dihydrochloride (diastereomer A-Compound 265):

(1R, 4R) -N was prepared from HCl in dioxane by Boc deprotection of ((1R, 4R) -4- ((4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) amino) cyclohexyl) aminomethyl tert-butyl ester (XI-ga) using the procedure described elsewhere¹- (4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) Cyclohexane-1, 4-diamine dihydrochloride. A solid was obtained as an amorphous white (70% yield).

(1R，4R)-N¹Synthesis of (4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) cyclohexane-1, 4-diamine dihydrochloride (diastereomer B-compound 266)

(1R, 4R) -M- (4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) cyclohexane-1, 4-diamine dihydrochloride was prepared from HCl in dioxane using the procedure described previously by deprotection of the Boc group of ((1R, 4R) -4- ((4- (5-bromo-1- (cyclohexylmethyl) -1H-indol-3-yl) cyclohexyl) amino) cyclohexyl) aminomethyl tert-butyl ester (XI-gb). A solid was obtained as an amorphous white (52% yield).

Salts of the compounds having formula F-I, I, or any subgroup thereof, may be prepared by subjecting the compounds to the desired acid. A method for compound 372 is depicted in scheme 12.

Synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile:

to a stirred solution of (3- ((3- (5-cyano-1-cyclohexyl-1H-indol-3-yl) -3- (3- (trifluoromethoxy) phenyl) propyl) amino) propyl) carbamic acid tert-butyl ester (500mg, 0.836mmol, 1 eq) in DCM (5mL) at 0 ℃ was added 4M HCl in 1, 4 dioxane (5mL) and stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC analysis. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain a crude compound. The crude compound was treated with saturated NaHCO₃The solution (20mL) was basified and extracted with DCM (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude compound was washed with diethyl ether to provide the product as a pale yellow solid (yield: 350mg, 84%).

¹H NMR(400MHz，DMSO-d₆)7.97(s，1H)，7.77(s，1H)，7.68(d，J＝8.6Hz，2H)，7.40(d，J＝9.3Hz，4H)，7.12(d，J＝6.7Hz，2H)，4.40(s，2H)，3.55(s，2H)，3.15(s，1H)，2.64(s，1H)，2.43-2.37(m，2H)，2.24(s，1H)，2.15(s，1H)，1.91(s，2H)，1.82(s，3H)，1.78-1.66(m，4H)，1.49(d，J＝12.4Hz，5H)，1.30(d，J＝17.8Hz，2H)，1.23(d，J＝10.8Hz，3H)

Synthesis of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile benzenesulfonate (S-1):

to a stirred solution of 3- (3- ((3-aminopropyl) amino) -1- (3- (trifluoromethoxy) phenyl) propyl) -1-cyclohexyl-1H-indole-5-carbonitrile (50mg, 0.100mmol, 1 eq) in ethanol (2mL) was added benzenesulfonic acid (19mg, 0.12mmol, 1.2 eq) at 0 ℃ and the reaction mixture was stirred at room temperature for 1H. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure at low temperature. The crude compound was washed with diethyl ether to provide the product as a white solid (yield: 38.6mg, 58%).

The salts of compound 372 listed in table 11 were prepared according to the procedure described in scheme 12 using the appropriate acid.

TABLE 11

TABLE 11

Characterization of the synthesized Compounds

Table XI below provides LC-MS data on the synthesized compound and indicates which general synthetic method (scheme number) was used to obtain the compound.

Table XII provides a summary of the NMR data for the synthesis of the compounds presented

Synthesis ofThe anti-infective activity of the compounds of (a)

The compounds disclosed by this application have anti-infective activity.

Initial Minimum Inhibitory Concentration (MIC) tests were performed on two bacterial strains:

escherichia coli (ATCC25922)

Staphylococcus aureus (ATCC 25923).

The results of these tests are shown in table XIII.

MIC of selected compounds was determined for a number of additional strains:

enterococcus faecalis (ATCC29212)

Pseudomonas aeruginosa (ATCC27853)

Staphylococcus aureus golden subspecies (ATCC29213)

Klebsiella pneumoniae subspecies pneumoniae (ATCC13883)

Streptococcus pneumoniae (ATCC33400)

Haemophilus influenzae (ATCC49766)

Neisseria meningitidis (ATCC13077)

Listeria monocytogenes (ATCC15313)

Legionella pneumophila subspecies pneumophila (ATCC33152)

Mycobacterium bovis BCG (ATCC19210)

The results of these tests are shown in table XIV.

Minimum Inhibitory Concentration (MIC)

Briefly, these compounds were dissolved in DMSO to 10 mM. and diluted to four times the highest concentration tested in cation-regulated Miller-Hinton broth (CAMHB). successive two-fold dilutions of CAMHB were performed in microdilution plates⁵CFU/mL. 50 μ l into CAMHBAn equal volume of inoculum was added to the volume of the batch. The trays were sealed in plastic bags and incubated at 35 ℃ for 16 to 20 hours. To help detect growth, the dye resazurin was added to a final concentration of 0.001% and incubated at room temperature for 1 h. Resazurin is reduced and thus a change in bacterial growth from blue to pink was observed. The MIC is the lowest concentration of compound that completely inhibits the growth of an organism.

The methods used are described in detail in: methods for Dilution antimicrobial susceptibility testing for Bacteria That Grow Aerobically [ Methods for Dilution antimicrobial susceptibility testing for Aerobically growing Bacteria ]; approved standard ninth edition. CLSI file M07-A9. Wien, pa: clinical and laboratory standardized institute; 2012.

inhibition of bacterial rnase P activity.

The assay is based on the extent to which the compound inhibits cleavage of the standard substrate pATSerUG by E.coli RNase P RNA, M1 RNA.

Substrate pATSerUG is a model substrate 45nt long, comprising a 5' leader sequence, an amino acid acceptor stem and an E.coli tRNA^SerThe T-stem/loop structure of the Su1 precursor. It was purchased from Dharmacon/general electric medical group (GE Healthcare) and used at the 5' end according to standard procedures³²P-tag ([ gamma-³²P]ATP) and purified by electrophoresis on denaturing polyacrylamide gels.

M1 RNA was produced by T7 in vitro transcription using a PCR product with the M1 RNA gene as a template.

The compound to be tested is dissolved in assay buffer (see below). The assay buffer is added up to a theoretical concentration of 10 mM. After vortexing and incubation at room temperature for 30 min, undissolved compounds were removed by centrifugation (17,000Xg 10 min). The concentration of the compound in the supernatant was determined by spectroscopy by measuring the absorbance at the wavelength at which the compound had the maximum absorbance. The calibration curve was made from known concentrations of the compounds dissolved in DMSO.

The cleavage reaction was performed in assay buffer (50mM Tris-HCl (pH 7.9), 1m MNH₄Cl、10mM MgCl₂、5％PEG6000、10mM spermidine).

M1 RNA was diluted to 10-fold the concentration to be used in the assay buffer and preincubated at 37 ℃ for 10min to allow for proper folding. The final concentration of M1 RNA was determined for each batch of enzyme and was the concentration that produced approximately 50% substrate cleavage in the 10min reaction. The folded M1 RNA was mixed with the compound to be tested in a total volume of 9. mu.l and incubated for a further 10min at 37 ℃. The substrates were preheated separately for 5min at 37 ℃. The reaction was initiated by adding 1. mu.l of substrate to the M1 RNA-compound mixture. After incubation at 37 ℃ for 10min, the reaction was stopped by adding 20. mu.l of stop solution (10M urea, 100mM EDTA, 0.05% bromophenol blue, 0.05% xylene nitrile blue). The reaction was then heated to 95 ℃ for 3min, cooled on ice, and the cleavage product was separated on denatured 20% polyacrylamide (7M urea/TBE) and detected using a phosphoimager. Signals were quantified using the software QuantityOne or ImageLab.

Initial screening for inhibition of RNase P Activity

To test whether any inhibition of the compound could be detected, the initial inhibition of rnase P activity was determined. The maximum amount of compound, i.e. 8. mu.l of supernatant from freshly dissolved compound in assay buffer, was used for 10. mu.l lysis reaction. The extent of inhibition was judged from normalized cleavage (the ratio between cleavage with compound divided by the understanding without compound). If this ratio is < 0.5, the IC50 value is determined (Table XIII).

IC₅₀And (4) determining.

About 8 different concentrations were tested for lysis, usually from the maximum concentration of the compound up to 8000-fold dilution. IC50 values and hill slopes were calculated using the software GraphPad Prism. The IC50 values determined are listed in table XIV.

Table XIII: RNase P inhibition and antibacterial efficacy results

NA: NI was not available: without inhibition

Table XIV: MICs of selected compounds against a range of bacteria

A. Gram-positive bacteria

B. Gram-negative bacteria